



**CaNoPy: A mixed-methods study of the care needs of individuals with idiopathic pulmonary fibrosis and their carers. A study protocol.**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-003537
Article Type:	Protocol
Date Submitted by the Author:	03-Jul-2013
Complete List of Authors:	Byrne, Anthony; Cardiff and Vale University Health Board, Sampson, Cathy; Cardiff University, Marie Curie Palliative Care Research Centre, School of Medicine Baillie, Jessica; Cardiff University, Marie Curie Palliative Care Research Centre, School of Medicine Harrison, Kim; Abertawe Bro Morgannwg University Health Board, Hope-Gill, Ben; Cardiff and Vale University Health Board, Hubbard, Richard; University of Nottingham, Faculty of Medicine and Health Sciences; Nottingham City Hospital, Griffiths, Gareth; Cardiff University, Wales Cancer Trials Unit, School of Medicine Nelson, Annmarie; Cardiff University, Marie Curie Palliative Care Research Centre, School of Medicine
<b>Primary Subject Heading</b>:	Respiratory medicine
Secondary Subject Heading:	Palliative care
Keywords:	Interstitial lung disease < THORACIC MEDICINE, QUALITATIVE RESEARCH, Adult palliative care < PALLIATIVE CARE

SCHOLARONE™  
Manuscripts

**Full title:**

CaNoPy: A mixed-methods study of the care needs of individuals with idiopathic pulmonary fibrosis and their carers. A study protocol.

**Short title:**

Care needs of individuals with idiopathic pulmonary fibrosis and their carers

**Author details:**

Anthony Byrne – corresponding author

Consultant in Palliative Medicine, Cardiff and Vale University Health Board

Director, Marie Curie Palliative Care Research Centre, Wales Cancer Trials Unit, Cardiff

University School of Medicine

6<sup>th</sup> Floor Neuadd Meirionnydd

Heath Park

Cardiff CF14 4YS

[Anthony.Byrne2@wales.nhs.uk](mailto:Anthony.Byrne2@wales.nhs.uk)

02920 687175

Cathy Sampson

Research Associate, Marie Curie Palliative Care Research Centre, Wales Cancer Trials Unit,

Cardiff University School of Medicine

[SampsonC2@cf.ac.uk](mailto:SampsonC2@cf.ac.uk)

Jessica Baillie

1  
2  
3 Research Associate, Marie Curie Palliative Care Research Centre, Wales Cancer Trials Unit,  
4  
5 Cardiff University School of Medicine  
6  
7 BaillieJ4@cf.ac.uk  
8  
9

10  
11  
12 Kim Harrison  
13  
14 Consultant Physician, Abertawe Bro Morgannwg University Health Board  
15  
16 Kim.Harrison@wales.nhs.uk  
17  
18

19  
20  
21 Ben Hope-Gill  
22  
23 Consultant Physician, Cardiff and Vale University Health Board  
24  
25 Ben.Hope-gill@wales.nhs.uk  
26  
27

28  
29  
30 Richard Hubbard  
31  
32 Professor of Respiratory Medicine, Nottingham City Hospital  
33  
34 GSK/British Lung Foundation Professor of Respiratory Epidemiology, Faculty of Medicine  
35  
36 & Health Sciences, University of Nottingham  
37  
38 Richard.hubbard@nottingham.ac.uk  
39  
40

41  
42  
43 Gareth Griffiths  
44  
45 Director, Wales Cancer Trials Unit, Cardiff University School of Medicine  
46  
47 GriffithsG@cf.ac.uk  
48  
49

50  
51  
52 Annmarie Nelson  
53  
54 Deputy Director, Marie Curie Palliative Care Research Centre, Wales Cancer Trials Unit,  
55  
56 Cardiff University School of Medicine  
57  
58

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

NelsonA9@cf.ac.uk

For peer review only

## ABSTRACT

**Introduction** Idiopathic pulmonary fibrosis (IPF) is a progressive, life threatening illness of unknown aetiology, with no proven pharmacological treatments. There is a limited evidence base indicating that the disease negatively affects quality of life, leading to increased dependence, restrictions on daily activities and fatigue. However, there is a paucity of in-depth information on disease impact across its trajectory, particularly in relation to unmet needs, outcomes of importance to patients and the experiences of carers. Furthermore, little is known about the support and information needs of individuals and their carers, or at what point individual need should trigger a referral to palliative care services.

**Methods and analysis** A mixed-methods study is proposed recruiting individuals with IPF at different stages of the disease and their carers from three respiratory centres in England and Wales. In-depth interviews will be undertaken with participants adopting an Interpretative Phenomenological Analysis approach. The study will also use validated questionnaires to explore quality of life (EQ-5D), depression (Hospital Anxiety and Depression Scale), breathlessness (Borg dyspnoea scale) and cough (Leicester Cough Questionnaire, Cough Symptom Score).

**Ethics and dissemination** Ethical approvals were gained in April 2012. Palliative care research is a developing field, but there has been limited focus on idiopathic pulmonary fibrosis. We anticipate that the results of the study will enable healthcare professionals to provide appropriate palliative care across the trajectory for individuals with the disease, and their carers, and we therefore aim to disseminate via relevant respiratory and palliative care

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

journals and conferences. We will also support the lay representative involved in the project to disseminate the findings to patient groups.

**KEYWORDS**

Idiopathic pulmonary fibrosis, carer, mixed-methods, Interpretative Phenomenological Analysis

**WORD COUNT**

4,281

For peer review only

## ARTICLE SUMMARY

### Article focus

- Idiopathic pulmonary fibrosis is a progressive, life threatening illness with high symptom burden. However there has been very limited research into patient perception of need, carer burden or patient/carer defined outcomes of importance in this population;
- A cross-sectional mixed-method study is proposed to explore the experiences and needs of individuals and their carers across the illness trajectory of idiopathic pulmonary fibrosis.

### Key messages

- The findings from this study should influence the care provided across the illness trajectory, particularly in terms of the information needs of individuals and carers at different stages of the disease, and identification of triggers for palliative care service involvement;
- The study will also determine outcomes of importance to patients which might influence both clinical service evaluation and the design of future interventional studies in IPF.

### Strengths and limitations of this study

- While this study is cross-sectional, rather than longitudinal, a large sample of patients at differences stages of the disease, and their relatives, will be included;
- This multi-centre study, in both England and Wales, will also adopt a mixed-methods approach, including qualitative interviews and the use of validated questionnaires.

## INTRODUCTION

Idiopathic pulmonary fibrosis (IPF) is a progressive, life-limiting condition characterised by chronic inflammation and scarring,[1] causing breathlessness and a dry cough in the individual.[2] The aetiology of IPF is unknown and the disease is progressive.[3] The illness trajectory of IPF is variable and a study from the United Kingdom (UK) found that individuals lived with the disease for a median of three years before death,[4] which is usually due to respiratory failure.[2] Identifying the prevalence of IPF is challenging as no mandatory monitoring register exists, but the overall incidence in the UK is 7.44 per 100,000, with more men and older people affected.[5] While anti-inflammatory, immunosuppressant and anti-fibrotic medications are prescribed for IPF;[1] no pharmacologic treatments are proven to treat IPF,[6] with the only significant treatment intervention being lung transplantation.

Lee et al. [7] describe a holistic approach to care for individuals with IPF, including: disease-management (including medications), promoting education and self-management, and symptom management. They further assert that palliative care should be fundamental and central to the management of IPF,[7] which has been similarly encouraged in recent clinical guidance from the National Institute for Health and Care Excellence (NICE) in the UK.[8]

Palliative care is defined by the World Health Organisation [9] as:

“an approach that improves the quality of life of patients and their families facing the problem associated with life-threatening illness, through the prevention and relief of suffering by means of early identification and impeccable assessment and treatment of pain and other problems, physical, psychosocial and spiritual”

However, there is a paucity of research considering at what stage palliative care should be offered to individuals with IPF, and what care and support patients feel would benefit them.



1  
2  
3  
4  
5 This protocol therefore describes a proposed cross-sectional mixed-methods study designed  
6  
7 to investigate the needs and experiences of individuals with idiopathic pulmonary fibrosis,  
8  
9 and their carers across, the illness trajectory.  
10

### 11 12 13 14 **Literature review**

15  
16 A literature search was undertaken using MEDLINE, CINAHL and PubMed, with additional  
17  
18 hand-searching of reference lists, to identify individuals' and carers' experiences of IPF and  
19  
20 the impact of the disease on their quality of life. The search identified several studies  
21  
22 considering quality of life for individuals with IPF, but fewer studies used a qualitative  
23  
24 approach to explore their experiences of the disease. A dearth of studies focussing on the  
25  
26 experiences of carers/ family members is also noted.  
27  
28

### 29 30 31 32 **Quality of life and IPF**

33  
34 The World Health Organisation [10] define quality of life as an individual's "perception of  
35  
36 their position in life in the context of the culture and value systems in which they live and in  
37  
38 relation to their goals, expectations, standards and concerns" (p.7). Furthermore, Swigris et  
39  
40 al. [11] assert that health-related quality of life is an individual's "perception of the impact of  
41  
42 health (in all its many facets) on his or her quality of life" (p.588). A systematic review by  
43  
44 Swigris et al. [11] revealed that a small number of studies consider the quality of life of  
45  
46 individuals with IPF. After a methodical literature search, Swigris et al. [11] identified only  
47  
48 seven studies that assessed quality of life in a total of 512 adults with IPF. The included  
49  
50 studies, which used the Medical Outcomes Study Short-Form 36-item tool (SF-36), World  
51  
52 Health Organisation Quality of Life 100-item tool (WHO-QOL) or the St George's  
53  
54 Respiratory Questionnaire (SGRQ), were conducted in Japan, the Netherlands, Brazil and the  
55  
56  
57  
58

1  
2  
3 United States of America (USA).[11] Health-related quality of life was found to be  
4 significantly lower than the general population in almost all domains, but particularly  
5 physical aspects such as respiratory symptoms, energy levels and degrees of  
6  
7 independence.[11] Specifically, dyspnoea was associated with worse quality of life.[11]  
8  
9  
10

11  
12  
13  
14 More recent studies considering quality of life have been identified since Swigris et al.'s [11]  
15 systematic review. An American cross-sectional study of 41 adults with IPF assessed fatigue,  
16 sleep quality and quality of life with validated tools: Pittsburgh sleep quality index, Epworth  
17 sleepiness scale and the SF-36.[12] Participants in Krishnan et al.'s [12] study reported  
18 significantly poorer sleep than the general population, and like Swigris et al. [11] identified  
19 that quality of life was significantly reduced in most domains, in particular physical aspects.  
20 Additionally, sleep quality was associated with reduced quality of life, which included  
21 physical and emotional measures,[12] and the authors thus recommend interventions to  
22 improve sleep quality. Few studies have adopted longitudinal approaches when considering  
23 quality of life in people with IPF. However, Tomioka et al. [13] adopted a cross-sectional  
24 and longitudinal approach, measuring quality of life using the SF-36 at baseline (n=46) and  
25 again at least 12 months later (n=32) for participants who had not died, developed other  
26 major diseases or lost to follow-up. At baseline, participants reported significantly reduced  
27 quality of life compared to the general population, while quality of life had worsened  
28 significantly longitudinally in terms of physical function and bodily pain.[13]  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

49 The small number of studies assessing the quality of life of people with IPF thus highlights  
50 significantly reduced outcomes, in particular in terms of physical health and sleep quality.  
51 However, no studies were identified that quantitatively measured relatives' or carers' quality  
52 of life when caring for an individual with this progressive, terminal disease. Nor have they  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 explored in detail the experiences underlying quality of life deterioration or patient/carer  
4 perceptions of interventions which might alter outcomes of importance. Of particular interest  
5 given the variable trajectory of the disease, is the identification of triggers for supportive and  
6 palliative interventions.  
7  
8  
9  
10

#### 11 12 13 14 Qualitative experiences of IPF

15  
16 Three studies were identified that explore the experiences of individuals with IPF using  
17 qualitative methods; although none of the studies discuss their methodological or  
18 philosophical approaches. Additionally, the papers do not discuss participants' disease  
19 stages.  
20  
21  
22  
23  
24

25  
26  
27 Swigris et al. [2] undertook focus groups or individual interviews with 20 adults living with  
28 IPF in the USA. The purpose of the study was to develop an IPF-sensitive health related  
29 quality of life measure by comparing the findings of the study to commonly-used global or  
30 respiratory tools. Dyspnoea and coughing were found to be distressing and impaired quality  
31 of life, medications for IPF caused significant side-effects, sleep quality was affected, low  
32 energy or exhaustion affected daily activities, forward planning was necessary and  
33 employment was either impossible or for some necessary to pay for medical care.[2]  
34  
35 Furthermore, participants were concerned about being a physical or financial burden,  
36 appreciation was expressed towards relatives, IPF led to decreased libido or inability to  
37 undertake sexual activity, social activities were limited, and participants were fearful about  
38 their health and recognised their mortality.[2] The authors concluded that an IPF-specific  
39 quality of life instrument is required as their participants' perspectives of the disease were not  
40 sufficiently reflected in generic tools.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Schoenheit et al. [14] undertook single in-depth interviews with 45 adults with IPF, from five  
4  
5 European countries: Spain, Italy, UK, France and Germany. Additionally, 18 relatives were  
6  
7 present during the interviews, although the article provides little insight into their  
8  
9 experiences. The authors used psychological techniques of asking participants to select  
10  
11 images that express their feelings and asking them to recall what was said in a particular  
12  
13 situation. The study also collated details of symptoms and revealed that dyspnoea was  
14  
15 experienced by 68% of participants, 59% reported a cough and 28% reported fatigue.[14]  
16  
17 The majority of participants had experienced delayed diagnoses and criticised the care they  
18  
19 received, while the minority of participants who were diagnosed promptly reported their care  
20  
21 more positively.[14] Both groups, however, reported rushed and insensitive diagnosis and a  
22  
23 lack of available information to them about the disease. IPF was found to have a substantial  
24  
25 impact on daily life in terms of reduced independence, difficulty in continuing relationships  
26  
27 and struggling financially through being unable to work.[14]  
28  
29  
30  
31  
32  
33

34 More recently, Bajwah et al. [15] interviewed eight patients with IPF, four carers (related to  
35  
36 different patients) and six healthcare professionals in the UK. They highlighted that patients  
37  
38 and carers had limited understanding of the disease, which made it difficult to plan ahead,  
39  
40 and that patients had not discussed end of life preferences.[15] While patients and carers  
41  
42 reported feeling satisfied with the care provided by the respiratory team, they also reported a  
43  
44 lack of coordination between different healthcare professionals and teams.[15]  
45  
46  
47  
48

49 IPF thus has a broad negative impact on everyday life for the individual, particularly in terms  
50  
51 of increased dependence on relatives, reduction in socialising, financial concerns, recognition  
52  
53 of mortality and a dearth of information. Bajwah et al. [15] included a small sample of carers  
54  
55 but do not explicate their needs while caring for an individual with IPF, while Schoenheit et  
56  
57  
58  
59  
60

1  
2  
3 al.'s [14] study included relatives but the authors make little reference to them in their paper.  
4  
5 Therefore, additional studies are required to understand carer experiences of IPF and what  
6  
7 support they require to care for a relative with the condition. Interrogating the experiences of  
8  
9 carers, and their needs, is crucial in a condition that is terminal and will thus require a high  
10  
11 level of support from those closest to the individual with IPF.  
12  
13

14  
15  
16 This protocol thus presents a study designed to explore the perspectives of both the individual  
17  
18 with IPF and their carer, at different stages of the disease.  
19  
20

## 21 22 23 24 25 **METHODS**

### 26 27 28 29 **Aim and objectives**

30  
31  
32 Aim: The aim of this study is to explore the needs of individuals with IPF and their families  
33  
34 across the illness trajectory.  
35  
36

#### 37 38 39 Objectives:

- 40  
41 1) Identify changes in individuals' and carers' perceived palliative care needs over the  
42  
43 progression of IPF in order to improve future service interventions;  
44
- 45  
46 2) Identify time-points or triggers at which palliative care services might effectively be  
47  
48 introduced;  
49
- 50  
51 3) Define the specific information needs of individuals and their carers;  
52
- 53  
54 4) Evaluate specifically the experiences and roles of the carer.  
55

### 56 57 58 59 60 **Methodology and methods**

1  
2  
3 The uncertain nature of disease progression makes a longitudinal study difficult to achieve in  
4 a set time frame and therefore a cross-sectional design with individuals at different stages of  
5 the IPF trajectory was chosen. To meet the aim and objectives of the study, a mixed-methods  
6 approach will be undertaken, encompassing the use of validated assessment tools (quality of  
7 life, anxiety and depression, and IPF symptoms) and in-depth interviews utilising Interpretive  
8 Phenomenological Analysis (IPA) methodology. Participants will be recruited and data  
9 collected from three National Health Service (NHS) respiratory centres, including two Health  
10 Boards within Wales and one NHS Trust in England.  
11  
12  
13  
14  
15  
16  
17  
18  
19

### 20 21 22 23 Recruitment and sampling

24 Individuals with IPF and their carers (a person of their choice who contributes most to their  
25 care, or at an earlier disease stage provides emotional support) will be recruited from the  
26 three respiratory centres, where a member of the clinical team will provide them with  
27 information about the study. Eligibility for the study will be decided by the clinical team  
28 according to a study proforma, which classifies individuals at different stages on the IPF  
29 trajectory and documents respiratory co-morbidities.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

40 The inclusion criteria for individuals will be a diagnosis of IPF and receiving medical care for  
41 IPF at one of the three centres, the ability to give informed consent to communicate  
42 sufficiently to take part in an interview. The inclusion criteria for carers include caring for an  
43 individual with IPF in the study, ability to give informed consent and communicate  
44 adequately to be interviewed. The exclusion criteria for individuals with IPF and carers will  
45 be any factor that prevents communication or comprehension. A disease typology was  
46 generated by palliative and respiratory consultants who are part of the research team to  
47 classify four different stages of the disease. To provide an insight into individuals', and thus  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

carers', needs across the disease trajectory, four groups of participants (see table 1) will be recruited, including people with:

1. Limited disease: forced vital capacity (FVC) greater than 50% predicted and gas transfer (TLCO) greater than 40% predicted;
2. Extensive disease: FVC less than 50% or TLCO less than 40% predicted;
3. Progressive disease: a fall in either FVC greater than 10% or TLCO greater than 15% during the previous 12 months;
4. Stable disease: a fall of less than 10% in FVC or less than 15% in TLCO in the previous 12 months.

Table one: participant group characteristics

<b>Participant group and characteristics</b>	Limited disease	Extensive disease
Progressive disease	6-10 individuals with IPF 6-10 carers	6-10 individuals with IPF 6-10 carers
Stable disease	6-10 individuals with IPF 6-10 carers	6-10 individuals with IPF 6-10 carers
		n= 48-80

Participants will be purposively sampled [16] to represent the four categories above, based on their FVC scores contained in their clinical notes, e.g. limited progressive, limited stable, extensive progressive, extensive stable. Congruent with the recommendations for Interpretative Phenomenological Analysis (IPA), the sample size for each group will be 6-10 individuals with IPF and 6-10 carers per homogenous group,[17] to represent a perspective

1  
2  
3 rather than a population. While the total sample size (n=48-80) is therefore large for the  
4  
5 methodology, it is necessary to gain insight into the perspectives of four groups of  
6  
7 participants.  
8

9  
10  
11 Potential participants will be provided with a participant information sheet, reply letter and  
12  
13 stamped addressed envelope by a member of the clinical team in the respiratory clinic, and  
14  
15 requested to return the reply slip to the research team if they are happy to be contacted to take  
16  
17 part in the study. Willing participants will then be telephoned by a researcher and an  
18  
19 interview will be arranged at a time and place convenient for them.  
20  
21

#### 22 23 24 25 Data collection

26  
27 Three data collection methods will be used in this study: recording of demographic and co-  
28  
29 morbidities data, questionnaires and in-depth interviews.  
30  
31

32  
33  
34 *Co-morbidities and demographic data* Demographic variables (age, marital status, location)  
35  
36 and co-morbidities (in particular chronic obstructive pulmonary disease, pulmonary  
37  
38 hypertension and lung cancer) of the individuals with IPF will be recorded by clinicians at the  
39  
40 clinic on a case report form.  
41  
42

43  
44  
45 *Questionnaires* Prior to the in-depth interview, individuals with IPF will be requested to  
46  
47 complete a booklet of questionnaires covering quality of life, anxiety and depression and  
48  
49 symptoms of IPF. These questionnaires will enable the research team to observe whether  
50  
51 quality of life, anxiety and depression change over time and how these correlate with  
52  
53 dyspnoea and coughing.  
54  
55



- 1) Quality of life (QOL): a validated, global health-related QOL tool will be used to evaluate quality of life in the form of the EQ-5D, which encompasses five questions on mobility, self-care, usual activities, pain/discomfort and anxiety/depression.[18] Swigris et al. [19] designed and tested a quality of life assessment tool specifically for IPF (ATAQ-IPF), but no other studies were identified that use this tool and therefore we opted for a more generic but well-validated tool.
- 2) Anxiety and depression: the validated Hospital Anxiety and Depression Scale (HADS) includes 14 questions and has been used widely across patient populations and found to be of high specificity and sensitivity.[20]
- 3) Breathlessness: a systematic review [21] found that dyspnoea assessment scales have not been validated for use in palliative care but also identified that the Borg dyspnoea scale, measuring severity of breathlessness on a numerical scale, appeared the most appropriate for use with this population.
- 4) Cough: the Leicester Cough Questionnaire is a 19-item self-completion tool measuring physical, psychological and social quality of life in relation to living with a chronic cough, which demonstrated high specificity and sensitivity.[22] The Cough Symptom Score [23] measures the severity of the cough on a visual analogue scale.

The researcher will assist participants to complete the questionnaires as required, which should take around 20 minutes, and this will occur before the interview to minimise the influence of topics discussed on questionnaire completion.

*In-depth interviews* IPA is as a qualitative psychological approach used to explore how people make sense of major events in their lives.[17] Three philosophical approaches influence IPA:[17] exploring the lived experience (phenomenology); interpretation of the phenomenon (hermeneutics); exploring the particular rather attempting generalise a group

1  
2  
3 (idiography). This methodology has previously been used successfully to explore palliative  
4 care issues, with both patients [24] and healthcare professionals.[25]  
5  
6  
7

8  
9  
10 To enable access to detailed personal accounts of how participants experience IPF [17], the  
11 research team will utilise semi-structured interviews with people with the disease and their  
12 carers. The interviews will be conducted at a place and time convenient for the participants,  
13 either in their homes or a quiet clinic location, or over the telephone if preferred. It is  
14 anticipated that the interviews will last between 30 and 60 minutes, with the interviewer  
15 terminating the discussion if they become concerned that the participant is unwell or fatigued.  
16  
17 We aim to interview individuals with IPF and carers separately, as is common in qualitative  
18 studies with both parties [26,27] and recommended by Smith et al.[17] If so, relatives will be  
19 interviewed first to allow individuals with IPF to have a break between completing the  
20 questionnaire and being interviewed. However, participants will be interviewed together if  
21 they prefer, which Cavers et al.[28] allowed in their qualitative study due to their participants  
22 with glioma struggling at times with communication. With participants' consent, interviews  
23 will be audio-recorded and transcribed verbatim.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

40 An interview schedule will be used (see Table 2) while also enabling participants to influence  
41 the agenda and discuss topics pertinent to them.[17] The interview process is dynamic and  
42 iterative and so the schedule will be reviewed after the first few interviews to assess whether  
43 alterations are necessary based on interviewee priorities.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table two: interview schedules

<b>Individuals with idiopathic pulmonary fibrosis</b>
<b>Diagnosis</b>
1. What symptoms were you experiencing when you were first diagnosed with IPF? What made you seek medical attention?
2. When and how did you get diagnosed with IPF?
3. Had you heard about the condition before? If yes, what did you know about it?
4. What information were you given about your illness? How useful did you find this information?
5. Did you seek out other information on IPF? If so what, how useful was it?
<b>Living with IPF</b>
6. How does your illness affect you? How has it impacted on your quality of life?
7. How have you been coping with or managing your illness?
8. Which services have you been receiving?
9. What do you think about the support that you have been receiving from health professionals?
10. Are there any gaps in the care that you have been receiving? What else could be done to help you?
<b>The future</b>
11. What is your understanding of how your illness will progress? Do you feel you have enough information about this? What else would you like to know?
12. Do you anticipate the need for more help later on? What kind of help do you think might need?
Is there anything else you've thought of that you would like to mention or discuss now?

**Carers****Diagnosis**

1. When and how did you first learn about (patient's name) illness?
2. What symptoms was (name) experiencing when they were first diagnosed with IPF?  
What made them seek medical attention?
3. Had you heard about the condition before? If yes, what did you know about it?
4. What information were you given about the illness? How useful did you find this information?
5. Did you seek out other information on IPF? If so, what and how useful was it?

**Living with IPF**

6. How does (name) illness affect them?
7. How have they been coping with these changes/ managing their illness?
8. How does (name) illness affect you? How has it impacted on your quality of life?
9. How have you been coping with these changes?
10. Have you been receiving any professional support or assistance?
11. What do you think about the support that you and (name) have been receiving from health professionals?
12. Are there any gaps in the care that (name) has been receiving? What else could be done to help you both?

**The future**

13. What is your understanding of how (name) illness will progress? Do you feel you have enough information about this? What else would you like to know?
14. Do you anticipate the need for more help later on? If so, what kind of help do you think might need?

1  
2  
3 Is there anything else you've thought of that you would like to mention or discuss now?  
4  
5  
6

7  
8 Data analysis

9  
10 While the quantitative and qualitative data will be analysed separately using appropriate  
11 methods, a complementary analysis of both data sets will seek to define key points or triggers  
12 for palliative care involvement. This will enable the identification of key components of  
13 participants' experiences of the IPF trajectory and clarify what possible interventions could  
14 be of benefit to patients and carers.  
15  
16  
17  
18  
19

20  
21  
22  
23 *Quantitative* The quantitative data will be analysed using SPSS.

- 24  
25 1. Descriptive statistics will be used to present the questionnaire data in graphic format  
26 and questionnaire-specific methodologies will be employed.  
27  
28 2. Categorical data will be presented as proportions with a 95% confidence interval (CI)  
29 and continuous data as means with a 95% CI. The limited size of the data set means  
30 that the analysis will be exploratory.  
31  
32  
33  
34  
35  
36  
37

38  
39 *Qualitative* IPA data analysis involves considering each case (participant) in turn and  
40 systematically interpreting how participants have interpreted their experience, before a  
41 narrative account of each case is developed.[17] A six step approach to data analysis is  
42 recommended by Smith et al.: [17]  
43  
44  
45  
46

- 47 1. Reading and rereading: listening to the interview and reading the transcript to  
48 familiarise oneself with the data and ensure that the participant is the focus of the  
49 analysis;  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

2. Initial noting: reading the transcript and noting anything important, including what is said (descriptive), the context of this (linguistic) and identifying patterns in the data and what these mean (conceptual);
3. Developing emerging themes: turning the notes into themes by summarising what is important in the transcript;
4. Connecting themes: this involves mapping how the emergent themes fit together;
5. Moving to the next case: repeating the process with each case, ensuring that each case is treated individually by trying to bracket out the findings from previous cases;
6. Patterns across cases: examining the cases for connections, considering how themes from one case feature in another and which themes are the strongest - redefining themes is common at this stage. The result should be super-ordinate themes and themes within.

The four different groups of participants will be analysed separately with comparison made between the groups. The research group will confer on the analysis to ensure that there is agreement across the themes. Tong et al. [29] recommend research triangulation to promote a deeper understanding of the phenomenon, and therefore 10% of the data will be double coded for agreement.

## **ETHICS AND DISSEMINATION**

### **Ethical considerations**

The study was approved by the university and regional National Health Service Research Ethics Committee in Wales and governance was gained from the three hospital sites in April 2012. The Research Governance Frameworks for England and Wales [30,31] and guidelines from the National Patient Safety Agency [32] were followed when designing the study.

1  
2  
3  
4  
5 Participants will have a minimum of 24 hours to decide whether to take part in the study and  
6  
7 the research team will ensure that participants are fully aware of the details of the research  
8  
9 prior to collecting written informed consent. Informed consent, which is central to ethical  
10  
11 research,[30] will be taken by a member of the research team who is experienced at doing so,  
12  
13 or by a member of the clinical team who has undertaken appropriate Good Clinical Practice  
14  
15 (research) training. The research team will ensure that all participants have the capacity to  
16  
17 consent in line with the Mental Capacity Act.[33] All data will be kept strictly confidential  
18  
19 according to the principles of the Data Protection Act [34] and data will be stored safely in  
20  
21 the research unit.  
22  
23  
24  
25

26  
27 There is growing impetus to include patients and the public in health and social care research  
28  
29 as members of the research team, rather than solely as participants, which Tischler et al. [35]  
30  
31 argue encourages the research to be relevant to patients. Therefore, in line with guidance  
32  
33 from Involving People [36] and Involve [37], the study documentation was reviewed by a lay  
34  
35 representative volunteer at the research centre hosting the study. The research centre has a  
36  
37 substantial model of consumer involvement and the nominated study volunteer will be  
38  
39 involved at all stages of the study and will attend regular meetings as a member of the  
40  
41 research team.  
42  
43  
44  
45

#### 46 47 **Validity and reliability/ rigour**

48  
49 Greene et al. [38] argue that mixed-methods studies enable triangulation of results, thus  
50  
51 increasing confidence in the findings of the research. Thus utilising in-depth interviews and  
52  
53 multiple questionnaires to explore participants' quality of life and experience across the  
54  
55

1  
2  
3 disease trajectory should promote complementarity [38] and deepen interpretations from the  
4  
5 study. Yardley [39] asserts characteristics of “good” qualitative research:  
6

- 7  
8 1. Sensitivity to context: the thorough literature review for this study promotes  
9  
10 sensitivity, which is supported by the clinical and research expertise of the research  
11  
12 team;
- 13  
14 2. Commitment and rigour; transparency and coherence: encouraged through the  
15  
16 proposed systematic and sufficient sampling, experienced qualitative researchers  
17  
18 collecting data and a multidisciplinary team of researchers analysing the data  
19  
20 systematically;
- 21  
22 3. Impact and importance: the objectives of the study are to generate evidence that can  
23  
24 be translated into clinical practice, in particular in relation to the information and  
25  
26 palliative service needs of individuals with IPF and their carers.  
27  
28

29  
30 Furthermore, we aim to promote validity in the use of validated assessment tools with high  
31  
32 specificity and sensitivity.  
33  
34  
35

### 36 **Limitations**

37  
38 One limitation of this study is the cross-sectional rather than longitudinal design. However,  
39  
40 as previously discussed, a longitudinal design is extremely challenging and resource intensive  
41  
42 due to the progressive and unpredictable nature of IPF. We believe that the chosen cross-  
43  
44 sectional design will provide representative data in an efficient and inclusive manner.  
45  
46

47  
48 Another limitation is the use of questionnaires that have not been specifically validated for  
49  
50 use with this clinical population. Therefore we have pragmatically selected tools that have  
51  
52 been used successfully with similar groups, are not too onerous for participants to complete  
53  
54 and provide a broad perspective of participants’ quality of life and provide insight into the  
55  
56 impact of IPF symptoms on everyday life.  
57  
58  
59  
60



## Dissemination

Palliative care research is a developing discipline with significant methodological challenges. It frequently aims to assess complex interventions in heterogeneous, vulnerable populations. Successful outcomes depend on robust methodological approaches which are complementary and which engage multidisciplinary researchers.[40,41] Identifying key points of intervention and outcomes of importance to patients are essential to both the development of well-designed pragmatic trials and the implementation of efficient, patient focused clinical services.

There is increasing focus on ensuring that palliative care services are available to and accessed by individuals with non-malignant diseases – with emphasis on need, not diagnosis.[42] Idiopathic pulmonary fibrosis is, as previously discussed, an under-researched disease. We anticipate that the results of this study will provide fundamental information considering the experiences and needs of individuals and their carers, both quantitatively and qualitatively, and will therefore be disseminated via relevant clinical and research journals and international conferences, encompassing both palliative care and respiratory specialities. The Chief Investigator and three of the Co-Investigators are Consultant Clinicians in palliative medicine and respiratory specialities, which will enable the planning and provision of appropriate palliative care services for both individuals with IPF and their carers, across the illness trajectory. Furthermore, the lay representative involved with the project will be supported to disseminate the results to relevant patient groups.

This paper has explored the incidence and symptoms of idiopathic pulmonary fibrosis, with discussion of the limited previous research undertaken in this area in terms of quality of life or experience of the disease. A paucity of research considering the experience and needs of

1  
2  
3 carers was also identified. This protocol has presented a planned multicentre mixed-methods  
4  
5 study in both England and Wales with people at different stages of IPF and their carers,  
6  
7 utilising validated questionnaires and in-depth interviews. The results of the study may help  
8  
9 healthcare professionals to plan and implement appropriate palliative care services for people  
10  
11 with IPF, and appropriate support for their carers.  
12  
13

#### 14 15 16 **Acknowledgment:**

17  
18 We wish to acknowledge the clinical teams who granted access and will support recruitment.  
19  
20

#### 21 22 23 **Competing interests:**

24  
25 None  
26  
27

#### 28 29 30 **Authors' contributions:**

31  
32 AB is the Chief Investigator, designed the study and reviewed the manuscript. CS contributed  
33  
34 to the protocol, reviewed the manuscript and will collect and analyse data. JB prepared the  
35  
36 manuscript. KH, BHG and RH are site Principal Investigators. GG designed the study. AN  
37  
38 designed the study and reviewed the manuscript.  
39  
40  
41

#### 42 43 **Funding:**

44  
45 This study was funded by Marie Curie Cancer Care.  
46  
47  
48

#### 49 50 **REFERENCES**

- 51  
52 1. Raghu G, Weycker D, Edelsberg J, Williamson B, Oster G. Incidence and prevalence of  
53  
54 idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2006;**174**(7):810 - 16  
55  
56  
57  
58  
59  
60

- 1  
2  
3 2. Swigris J, Stewart A, Gould M, Wilson S. Patients' perspectives on how idiopathic  
4  
5 pulmonary fibrosis affects the quality of their lives. *Health Qual Life Outcomes*  
6  
7 2005;**3**:61 - 69  
8
- 9  
10 3. Selman M, King T, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving  
11  
12 hypotheses about its pathogenesis and implications for therapy. *Ann Intern Med*  
13  
14 2001;**134**(2):136 - 51  
15
- 16  
17 4. Gribbin J, Hubbard R, Le Jeune I, Smith C, West J, Tata L. Incidence and mortality of  
18  
19 idiopathic pulmonary fibrosis and sarcoidosis in the UK. *Thorax* 2006;**61**(11):980 - 85  
20
- 21  
22 5. Navaratnam V, Fleming K, West J, et al. The rising incidence of idiopathic pulmonary  
23  
24 fibrosis in the UK. *Thorax* 2011;**66**(6):462 - 67  
25
- 26  
27 6. Raghu G, Collard H, Egan J, et al., on behalf of the ATS/ERS/JRS/ALAT Committee on  
28  
29 Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement:  
30  
31 idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and  
32  
33 management. *Am J Respir Crit Care Med* 2011;**183**(6):788 - 824  
34
- 35  
36 7. Lee J, McLaughlin S, Collard H. Comprehensive care of the patient with idiopathic  
37  
38 pulmonary fibrosis. *Curr Opin Pulm Med* 2011;**17**(5):348 - 54  
39
- 40  
41 8. National Institute for Health and Care Excellence. Idiopathic pulmonary fibrosis: diagnosis  
42  
43 and management of suspected idiopathic pulmonary fibrosis.  
44  
45 <http://www.nice.org.uk/nicemedia/live/14183/64124/64124.pdf>, 2013.  
46
- 47  
48 9. World Health Organisation. WHO Definition of Palliative Care.  
49  
50 <http://www.who.int/cancer/palliative/definition/en/>, 2012.  
51
- 52  
53 10. World Health Organisation. WHOQOL Measuring Quality of Life.  
54  
55 [http://www.who.int/mental\\_health/media/68.pdf](http://www.who.int/mental_health/media/68.pdf), 1997.  
56  
57  
58  
59  
60

- 1  
2  
3 11. Swigris J, Kuschner W, Jacobs S, Wilson S, Gould M. Health-related quality of life in  
4  
5 patients with idiopathic pulmonary fibrosis: a systematic review. *Thorax* 2005;**60**:558  
6  
7 - 94  
8
- 9  
10 12. Krishnan V, McCormack M, Mathai S, et al. Sleep quality and health-related quality of  
11  
12 life in idiopathic pulmonary disease. *Chest* 2008;**134**(4):693 - 98  
13
- 14 13. Tamioka H, Imanaka K, Hashimoto K, Iwasaki H. Health-related quality of life in  
15  
16 patients with idiopathic pulmonary fibrosis - cross-sectional and longitudinal study.  
17  
18 *Intern Med* 2007;**46**(18):1533 - 42  
19
- 20 14. Scheonheit G, Becattelli I, Cohen A. Living with idiopathic pulmonary fibrosis: an in-  
21  
22 depth qualitative survey of European patients. *Chron Respir Dis* 2011;**8**(4):225 - 31  
23  
24
- 25 15. Bajwah S, Koffman J, Higginson I, et al. 'I wish I knew more...' the end-of-life planning  
26  
27 and information needs for end-stage fibrotic interstitial lung disease: views of  
28  
29 patients, carers and health professionals. *BMJ Support Palliat Care* 2013;**3**:84 - 90  
30  
31
- 32 16. Patton M. *Qualitative Research and Evaluation Methods (3rd edn)*. London: Sage, 2002.  
33
- 34 17. Smith J, Flowers P, Larkin M. *Interpretative Phenomenological Analysis: Theory,*  
35  
36 *Method and Research*. Los Angeles: Sage, 2009: 1 - 232.  
37
- 38 18. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group.  
39  
40 *Annals of Medicine* 2001;**33**(5):337 - 43  
41  
42
- 43 19. Swigris J, Wilson S, Green K, Sprunger D, Brown K, Wamboldt F. Development of the  
44  
45 ATAQ-IPF: a tool to assess quality of life in IPF. *Health Qual Life Outcomes*  
46  
47 2010;**8**:77 - 85  
48
- 49 20. Bjelland I, Dahl A, Haug T, Neckelmann D. The validity of the Hospital Anxiety and  
50  
51 Depression Scale: An updated literature review. *J Psychosom Res* 2002;**52**(2):69 - 77  
52  
53
- 54 21. Dorman S, Byrne A, Edwards A. Which measurement scales should we use to measure  
55  
56 breathlessness in palliative care? A systematic review. *Palliat Med* 2007;**21**(3):177-91  
57  
58

- 1  
2  
3 22. Biring S, Prudon B, Carr A, Singh S, Morgan M, Pavord I. Development of a symptom  
4 specific health status measure for patients with chronic cough: Leicester Cough  
5 Questionnaire (LCQ). *Thorax* 2003;**58**(4):339 - 43  
6  
7  
8  
9  
10 23. Jones R, Hilldrup S, Hope-Gill B, Eccles R, Harrison N. Mechanical induction of cough  
11 in Idiopathic Pulmonary Fibrosis. *Cough* 2011;**7**:2 - 12  
12  
13  
14 24. Seamark D, Blake S, Seamark C, Halpin D. Living with severe chronic obstructive  
15 pulmonary disease (COPD): perceptions of patients and their carers: An interpretative  
16 phenomenological analysis. *Palliat Med* 2004;**18**(7):619 - 25  
17  
18  
19  
20 25. Taubert M, Noble S, Nelson A. What challenges good palliative care provision out-of-  
21 hours? A qualitative interview study of out-of-hours general practitioners. *Palliat*  
22 *Med* 2011;**1**:13 - 18  
23  
24  
25  
26  
27 26. Orrevall Y, Tishelman C, Permert J. Home parenteral nutrition: A qualitative interview  
28 study of the experiences of advanced cancer patients and their families. *Clin Nutr*  
29 *2005*;**24**(6):961 - 70  
30  
31  
32  
33  
34 27. White Y, Grenyer B. The biopsychosocial impact of end-stage renal disease: the  
35 experience of dialysis patients and their partners. *J Adv Nurs* 1999;**30**(6):1312 - 29  
36  
37  
38 28. Cavers D, Hacking B, Erridge S, Morris P, Kendall M, Murray S. Adjustment and support  
39 needs of glioma patients and their relatives: serial interviews. *Psychooncology*  
40 *2012*;DOI 10.1002/pon.3136.  
41  
42  
43  
44  
45 29. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research  
46 (COREQ): a 32-item checklist for interviews and focus groups. *Int J Qual Health Care*  
47 *2007*;**19**(6):349 - 57  
48  
49  
50  
51  
52 30. Department of Health. Research Governance Framework for Health and Social Care (2nd  
53 edn.).  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 [http://www.dh.gov.uk/prod\\_consum\\_dh/groups/dh\\_digitalassets/@dh/@en/document](http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/document)  
4  
5 [s/digitalasset/dh\\_4122427.pdf](http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/document) 2005.  
6  
7  
8 31. Welsh Assembly Government. Research Governance Framework for Health and Social  
9  
10 Care in Wales (2nd ed.).  
11  
12 [http://cymru.gov.uk/topics/health/research/word/publications/researchgovernance/?lan](http://cymru.gov.uk/topics/health/research/word/publications/researchgovernance/?lang=en)  
13  
14 [g=en](http://cymru.gov.uk/topics/health/research/word/publications/researchgovernance/?lang=en)] 2009.  
15  
16 32. National Patient Safety Agency. Information Sheets and Consent Forms: Guidance for  
17  
18 Researchers and Reviewers.  
19  
20 [www.nres.nhs.uk/EasySiteWeb/GatewayLink.aspx?allId=338](http://www.nres.nhs.uk/EasySiteWeb/GatewayLink.aspx?allId=338), 2011.  
21  
22  
23 33. United Kingdom. Mental Capacity Act 2005.  
24  
25 [http://www.opsi.gov.uk/acts/acts2005/ukpga\\_20050009\\_en\\_1](http://www.opsi.gov.uk/acts/acts2005/ukpga_20050009_en_1) 2005.  
26  
27  
28 34. United Kingdom. Data Protection Act 1998.  
29  
30 [http://www.opsi.gov.uk/acts/acts1998/ukpga\\_19980029\\_en\\_1](http://www.opsi.gov.uk/acts/acts1998/ukpga_19980029_en_1) 1998.  
31  
32 35. Tischler V, D'Silva K, Cheetham A, Goring M, Calton T. Involving patients in research:  
33  
34 the challenge of patient-centredness. *Int J Soc Psychiatry* 2010;**56**(6):623 - 33  
35  
36 36. Moore B, Porteous C, Simon N. Pathways for Involving People in Social Care and Health  
37  
38 Research in Wales: A Signposting Document. <http://www.involvingpeople.org.uk/>,  
39  
40 2007.  
41  
42 37. Vale C, Fitzgibbon J, Hanley B, et al. Public involvement in clinical trials: Supplement to  
43  
44 the briefing notes for researchers. [http://www.invo.org.uk/wp-](http://www.invo.org.uk/wp-content/uploads/2012/04/INVOLVEpublicinvolvementinclinicaltrialsBriefingnotes2012.pdf)  
45  
46 [content/uploads/2012/04/INVOLVEpublicinvolvementinclinicaltrialsBriefingnotes20](http://www.invo.org.uk/wp-content/uploads/2012/04/INVOLVEpublicinvolvementinclinicaltrialsBriefingnotes2012.pdf)  
47  
48 [12.pdf](http://www.invo.org.uk/wp-content/uploads/2012/04/INVOLVEpublicinvolvementinclinicaltrialsBriefingnotes2012.pdf), 2012.  
49  
50  
51 38. Greene J, Caracelli V, Graham W. Toward a conceptual framework for mixed-method  
52  
53 evaluation designs. *Education Evaluation and Policy Analysis* 1989;**11**(3):255 - 74  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 39. Yardley L. Dilemmas in qualitative health research. *Psychology and Health*  
4  
5 2000;**15**(2):215 - 28  
6  
7  
8 40. Byrne A, Hood K, Griffiths G, Maughan T. Design and conduct of research and clinical  
9  
10 trials. In: Walsh D, Caraceni A, Fainsinger R, et al., eds. *Palliative Medicine*.  
11  
12 Philadelphia: Saunders Elsevier, 2009.  
13  
14 41. Kaasa S, Hjermstad M, Loge J. Methodological and structural challenges in palliative  
15  
16 care research: how have we fared in the last decades? *Palliat Med* 2006;**20**(8):727 - 34  
17  
18 42. Fallon M, Foley P. Rising to the challenge of palliative care for non-malignant disease.  
19  
20  
21 *Palliat Med* 2012;**26**(2):99 - 100  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**A mixed-methods study of the Care Needs of individuals with idiopathic Pulmonary fibrosis and their carers: CaNoPy. A study protocol.**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-003537.R1
Article Type:	Protocol
Date Submitted by the Author:	05-Jul-2013
Complete List of Authors:	Byrne, Anthony; Cardiff and Vale University Health Board, Sampson, Cathy; Cardiff University, Marie Curie Palliative Care Research Centre, School of Medicine Baillie, Jessica; Cardiff University, Marie Curie Palliative Care Research Centre, School of Medicine Harrison, Kim; Abertawe Bro Morgannwg University Health Board, Hope-Gill, Ben; Cardiff and Vale University Health Board, Hubbard, Richard; University of Nottingham, Faculty of Medicine and Health Sciences; Nottingham City Hospital, Griffiths, Gareth; Cardiff University, Wales Cancer Trials Unit, School of Medicine Nelson, Annmarie; Cardiff University, Marie Curie Palliative Care Research Centre, School of Medicine
<b>Primary Subject Heading</b>:	Respiratory medicine
Secondary Subject Heading:	Palliative care
Keywords:	Interstitial lung disease < THORACIC MEDICINE, QUALITATIVE RESEARCH, Adult palliative care < PALLIATIVE CARE

SCHOLARONE™  
Manuscripts



**Full title:**

A mixed-methods study of the Care Needs of individuals with idiopathic Pulmonary fibrosis and their carers: CaNoPy. A study protocol.

**Short title:**

Care needs of individuals with idiopathic pulmonary fibrosis and their carers

**Author details:**

Anthony Byrne – corresponding author

Consultant in Palliative Medicine, Cardiff and Vale University Health Board

Director, Marie Curie Palliative Care Research Centre, Wales Cancer Trials Unit, Cardiff

University School of Medicine

6<sup>th</sup> Floor Neuadd Meirionnydd

Heath Park

Cardiff CF14 4YS

[Anthony.Byrne2@wales.nhs.uk](mailto:Anthony.Byrne2@wales.nhs.uk)

02920 687175

Cathy Sampson

Research Associate, Marie Curie Palliative Care Research Centre, Wales Cancer Trials Unit,

Cardiff University School of Medicine

[SampsonC2@cf.ac.uk](mailto:SampsonC2@cf.ac.uk)

Jessica Baillie

1  
2  
3 Research Associate, Marie Curie Palliative Care Research Centre, Wales Cancer Trials Unit,  
4  
5 Cardiff University School of Medicine  
6  
7 BaillieJ4@cf.ac.uk  
8  
9

10  
11  
12 Kim Harrison  
13  
14 Consultant Physician, Abertawe Bro Morgannwg University Health Board  
15  
16 Kim.Harrison@wales.nhs.uk  
17  
18

19  
20  
21 Ben Hope-Gill  
22  
23 Consultant Physician, Cardiff and Vale University Health Board  
24  
25 Ben.Hope-gill@wales.nhs.uk  
26  
27

28  
29  
30 Richard Hubbard  
31  
32 Professor of Respiratory Medicine, Nottingham City Hospital  
33  
34 GSK/British Lung Foundation Professor of Respiratory Epidemiology, Faculty of Medicine  
35  
36 & Health Sciences, University of Nottingham  
37  
38 Richard.hubbard@nottingham.ac.uk  
39  
40

41  
42  
43 Gareth Griffiths  
44  
45 Director, Wales Cancer Trials Unit, Cardiff University School of Medicine  
46  
47 GriffithsG@cf.ac.uk  
48  
49

50  
51  
52 Annmarie Nelson  
53  
54 Deputy Director, Marie Curie Palliative Care Research Centre, Wales Cancer Trials Unit,  
55  
56 Cardiff University School of Medicine  
57  
58

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

NelsonA9@cf.ac.uk

For peer review only

## ABSTRACT

**Introduction** Idiopathic pulmonary fibrosis (IPF) is a progressive, life threatening illness of unknown aetiology, with no proven pharmacological treatments. There is a limited evidence base indicating that the disease negatively affects quality of life, leading to increased dependence, restrictions on daily activities and fatigue. However, there is a paucity of in-depth information on disease impact across its trajectory, particularly in relation to unmet needs, outcomes of importance to patients and the experiences of carers. Furthermore, little is known about the support and information needs of individuals and their carers, or at what point individual need should trigger a referral to palliative care services.

**Methods and analysis** A mixed-methods study is proposed recruiting individuals with IPF at different stages of the disease and their carers from three respiratory centres in England and Wales. In-depth interviews will be undertaken with participants adopting an Interpretative Phenomenological Analysis approach. The study will also use validated questionnaires to explore quality of life (EQ-5D), depression (Hospital Anxiety and Depression Scale), breathlessness (Borg dyspnoea scale) and cough (Leicester Cough Questionnaire, Cough Symptom Score).

**Ethics and dissemination** Ethical approvals were gained in April 2012. Palliative care research is a developing field, but there has been limited focus on idiopathic pulmonary fibrosis. We anticipate that the results of the study will enable healthcare professionals to provide appropriate palliative care across the trajectory for individuals with the disease, and their carers, and we therefore aim to disseminate via relevant respiratory and palliative care

1  
2  
3 journals and conferences. We will also support the lay representative involved in the project  
4  
5 to disseminate the findings to patient groups.  
6  
7  
8

9  
10 **KEYWORDS**

11 Idiopathic pulmonary fibrosis, carer, mixed-methods, Interpretative Phenomenological  
12  
13 Analysis  
14  
15

16  
17  
18 **WORD COUNT**

19 4,339  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ARTICLE SUMMARY

### Article focus

- Idiopathic pulmonary fibrosis is a progressive, life threatening illness with high symptom burden. However there has been very limited research into patient perception of need, carer burden or patient/carer defined outcomes of importance in this population;
- A cross-sectional mixed-method study is proposed to explore the experiences and needs of individuals and their carers across the illness trajectory of idiopathic pulmonary fibrosis.

### Key messages

- The findings from this study should influence the care provided across the illness trajectory, particularly in terms of the information needs of individuals and carers at different stages of the disease, and identification of triggers for palliative care service involvement;
- The study will also determine outcomes of importance to patients which might influence both clinical service evaluation and the design of future interventional studies in IPF.

### Strengths and limitations of this study

- While this study is cross-sectional, rather than longitudinal, a large sample of patients at differences stages of the disease, and their relatives, will be included;
- This multi-centre study, in both England and Wales, will also adopt a mixed-methods approach, including qualitative interviews and the use of validated questionnaires.

## INTRODUCTION

Idiopathic pulmonary fibrosis (IPF) is a progressive, life-limiting condition characterised by chronic inflammation and scarring,[1] causing breathlessness and a dry cough in the individual.[2] The aetiology of IPF is unknown and the disease is progressive.[3] The illness trajectory of IPF is variable and a study from the United Kingdom (UK) found that individuals lived with the disease for a median of three years before death,[4] which is usually due to respiratory failure.[2] Identifying the prevalence of IPF is challenging as no mandatory monitoring register exists, but the overall incidence in the UK is 7.44 per 100,000, with more men and older people affected.[5] While anti-inflammatory, immunosuppressant and anti-fibrotic medications are prescribed for IPF;[1] no pharmacologic treatments are proven to treat IPF,[6] with the only significant treatment intervention being lung transplantation.

Lee et al. [7] describe a holistic approach to care for individuals with IPF, including: disease-management (including medications), promoting education and self-management, and symptom management. They further assert that palliative care should be fundamental and central to the management of IPF,[7] which has been similarly encouraged in recent clinical guidance from the National Institute for Health and Care Excellence (NICE) in the UK.[8] Palliative care is defined by the World Health Organisation [9] as:

“an approach that improves the quality of life of patients and their families facing the problem associated with life-threatening illness, through the prevention and relief of suffering by means of early identification and impeccable assessment and treatment of pain and other problems, physical, psychosocial and spiritual”

1  
2  
3 However, there is a paucity of research considering at what stage palliative care should be  
4 offered to individuals with IPF, and what care and support patients feel would benefit them.  
5  
6  
7

8  
9  
10 This protocol therefore describes a proposed cross-sectional mixed-methods study (CaNoPy:  
11 Care Needs of individuals with idiopathic Pulmonary fibrosis and their carers) designed to  
12 investigate the needs and experiences of individuals with idiopathic pulmonary fibrosis, and  
13 their carers across, the illness trajectory.  
14  
15  
16  
17

### 18 19 20 21 **Literature review**

22  
23 A literature search was undertaken using MEDLINE, CINAHL and PubMed, with additional  
24 hand-searching of reference lists, to identify individuals' and carers' experiences of IPF and  
25 the impact of the disease on their quality of life. The search identified several studies  
26 considering quality of life for individuals with IPF, but fewer studies used a qualitative  
27 approach to explore their experiences of the disease. A dearth of studies focussing on the  
28 experiences of carers/ family members is also noted.  
29  
30  
31  
32  
33  
34  
35  
36  
37

### 38 39 **Quality of life and IPF**

40  
41 The World Health Organisation [10] define quality of life as an individual's "perception of  
42 their position in life in the context of the culture and value systems in which they live and in  
43 relation to their goals, expectations, standards and concerns" (p.7). Furthermore, Swigris et  
44 al. [11] assert that health-related quality of life is an individual's "perception of the impact of  
45 health (in all its many facets) on his or her quality of life" (p.588). A systematic review by  
46 Swigris et al. [11] revealed that a small number of studies consider the quality of life of  
47 individuals with IPF. After a methodical literature search, Swigris et al. [11] identified only  
48 seven studies that assessed quality of life in a total of 512 adults with IPF. The included  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 studies, which used the Medical Outcomes Study Short-Form 36-item tool (SF-36), World  
4 Health Organisation Quality of Life 100-item tool (WHO-QOL) or the St George's  
5 Respiratory Questionnaire (SGRQ), were conducted in Japan, the Netherlands, Brazil and the  
6 United States of America (USA).[11] Health-related quality of life was found to be  
7 significantly lower than the general population in almost all domains, but particularly  
8 physical aspects such as respiratory symptoms, energy levels and degrees of  
9 independence.[11] Specifically, dyspnoea was associated with worse quality of life.[11]

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21 More recent studies considering quality of life have been identified since Swigris et al.'s [11]  
22 systematic review. An American cross-sectional study of 41 adults with IPF assessed fatigue,  
23 sleep quality and quality of life with validated tools: Pittsburgh sleep quality index, Epworth  
24 sleepiness scale and the SF-36.[12] Participants in Krishnan et al.'s [12] study reported  
25 significantly poorer sleep than the general population, and like Swigris et al. [11] identified  
26 that quality of life was significantly reduced in most domains, in particular physical aspects.  
27 Additionally, sleep quality was associated with reduced quality of life, which included  
28 physical and emotional measures,[12] and the authors thus recommend interventions to  
29 improve sleep quality. Few studies have adopted longitudinal approaches when considering  
30 quality of life in people with IPF. However, Tomioka et al. [13] adopted a cross-sectional  
31 and longitudinal approach, measuring quality of life using the SF-36 at baseline (n=46) and  
32 again at least 12 months later (n=32) for participants who had not died, developed other  
33 major diseases or lost to follow-up. At baseline, participants reported significantly reduced  
34 quality of life compared to the general population, while quality of life had worsened  
35 significantly longitudinally in terms of physical function and bodily pain.[13]

1  
2  
3 The small number of studies assessing the quality of life of people with IPF thus highlights  
4 significantly reduced outcomes, in particular in terms of physical health and sleep quality.  
5  
6  
7 However, no studies were identified that quantitatively measured relatives' or carers' quality  
8 of life when caring for an individual with this progressive, terminal disease. Nor have they  
9 explored in detail the experiences underlying quality of life deterioration or patient/carer  
10 perceptions of interventions which might alter outcomes of importance. Of particular interest  
11 given the variable trajectory of the disease, is the identification of triggers for supportive and  
12 palliative interventions.  
13  
14  
15  
16  
17  
18  
19

### 20 21 22 23 Qualitative experiences of IPF

24  
25 Three studies were identified that explore the experiences of individuals with IPF using  
26 qualitative methods; although none of the studies discuss their methodological or  
27 philosophical approaches. Additionally, the papers do not discuss participants' disease  
28 stages.  
29  
30  
31  
32  
33

34  
35  
36 Swigris et al. [2] undertook focus groups or individual interviews with 20 adults living with  
37 IPF in the USA. The purpose of the study was to develop an IPF-sensitive health related  
38 quality of life measure by comparing the findings of the study to commonly-used global or  
39 respiratory tools. Dyspnoea and coughing were found to be distressing and impaired quality  
40 of life, medications for IPF caused significant side-effects, sleep quality was affected, low  
41 energy or exhaustion affected daily activities, forward planning was necessary and  
42 employment was either impossible or for some necessary to pay for medical care.[2]  
43  
44 Furthermore, participants were concerned about being a physical or financial burden,  
45 appreciation was expressed towards relatives, IPF led to decreased libido or inability to  
46 undertake sexual activity, social activities were limited, and participants were fearful about  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 their health and recognised their mortality.[2] The authors concluded that an IPF-specific  
4 quality of life instrument is required as their participants' perspectives of the disease were not  
5 sufficiently reflected in generic tools.  
6  
7  
8

9  
10  
11 Schoenheit et al. [14] undertook single in-depth interviews with 45 adults with IPF, from five  
12 European countries: Spain, Italy, UK, France and Germany. Additionally, 18 relatives were  
13 present during the interviews, although the article provides little insight into their  
14 experiences. The authors used psychological techniques of asking participants to select  
15 images that express their feelings and asking them to recall what was said in a particular  
16 situation. The study also collated details of symptoms and revealed that dyspnoea was  
17 experienced by 68% of participants, 59% reported a cough and 28% reported fatigue.[14]  
18  
19 The majority of participants had experienced delayed diagnoses and criticised the care they  
20 received, while the minority of participants who were diagnosed promptly reported their care  
21 more positively.[14] Both groups, however, reported rushed and insensitive diagnosis and a  
22 lack of available information to them about the disease. IPF was found to have a substantial  
23 impact on daily life in terms of reduced independence, difficulty in continuing relationships  
24 and struggling financially through being unable to work.[14]  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

43 More recently, Bajwah et al. [15] interviewed eight patients with IPF, four carers (related to  
44 different patients) and six healthcare professionals in the UK. They highlighted that patients  
45 and carers had limited understanding of the disease, which made it difficult to plan ahead,  
46 and that patients had not discussed end of life preferences.[15] While patients and carers  
47 reported feeling satisfied with the care provided by the respiratory team, they also reported a  
48 lack of coordination between different healthcare professionals and teams.[15]  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 IPF thus has a broad negative impact on everyday life for the individual, particularly in terms  
4  
5 of increased dependence on relatives, reduction in socialising, financial concerns, recognition  
6  
7 of mortality and a dearth of information. Bajwah et al. [15] included a small sample of carers  
8  
9 but do not explicate their needs while caring for an individual with IPF, while Schoenheit et  
10  
11 al.'s [14] study included relatives but the authors make little reference to them in their paper.  
12  
13 Therefore, additional studies are required to understand carer experiences of IPF and what  
14  
15 support they require to care for a relative with the condition. Interrogating the experiences of  
16  
17 carers, and their needs, is crucial in a condition that is terminal and will thus require a high  
18  
19 level of support from those closest to the individual with IPF.  
20  
21  
22  
23  
24

25 This protocol thus presents a study designed to explore the perspectives of both the individual  
26  
27 with IPF and their carer, at different stages of the disease.  
28  
29  
30  
31  
32

## 33 **METHODS**

### 34 **Aim and objectives**

35  
36  
37  
38  
39  
40 Aim: The aim of this study is to explore the needs of individuals with IPF and their families  
41  
42 across the illness trajectory.  
43  
44  
45

46  
47 Objectives:

- 48  
49 1) Identify changes in individuals' and carers' perceived palliative care needs over the  
50  
51 progression of IPF in order to improve future service interventions;  
52  
53
- 54  
55 2) Identify time-points or triggers at which palliative care services might effectively be  
56  
57 introduced;  
58  
59

- 3) Define the specific information needs of individuals and their carers;
- 4) Evaluate specifically the experiences and roles of the carer.

### **Methodology and methods**

The uncertain nature of disease progression makes a longitudinal study difficult to achieve in a set time frame and therefore a cross-sectional design with individuals at different stages of the IPF trajectory was chosen. To meet the aim and objectives of the study, a mixed-methods approach will be undertaken, encompassing the use of validated assessment tools (quality of life, anxiety and depression, and IPF symptoms) and in-depth interviews utilising Interpretive Phenomenological Analysis (IPA) methodology. Participants will be recruited and data collected from three National Health Service (NHS) respiratory centres, including two Health Boards within Wales and one NHS Trust in England.

#### **Recruitment and sampling**

Individuals with IPF and their carers (a person of their choice who contributes most to their care, or at an earlier disease stage provides emotional support) will be recruited from the three respiratory centres, where a member of the clinical team will provide them with information about the study. Eligibility for the study will be decided by the clinical team according to a study proforma, which classifies individuals at different stages on the IPF trajectory and documents respiratory co-morbidities.

The inclusion criteria for individuals will be a diagnosis of IPF and receiving medical care for IPF at one of the three centres, the ability to give informed consent to communicate sufficiently to take part in an interview. The inclusion criteria for carers include caring for an individual with IPF in the study, ability to give informed consent and communicate

adequately to be interviewed. The exclusion criteria for individuals with IPF and carers will be any factor that prevents communication or comprehension. A disease typology was generated by palliative and respiratory consultants who are part of the research team to classify four different stages of the disease. To provide an insight into individuals', and thus carers', needs across the disease trajectory, four groups of participants (see table 1) will be recruited, including people with:

1. Limited disease: forced vital capacity (FVC) greater than 50% predicted and gas transfer (TLCO) greater than 40% predicted;
2. Extensive disease: FVC less than 50% or TLCO less than 40% predicted;
3. Progressive disease: a fall in either FVC greater than 10% or TLCO greater than 15% during the previous 12 months;
4. Stable disease: a fall of less than 10% in FVC or less than 15% in TLCO in the previous 12 months.

Table one: participant group characteristics

<b>Participant group and characteristics</b>	Limited disease	Extensive disease
Progressive disease	6-10 individuals with IPF 6-10 carers	6-10 individuals with IPF 6-10 carers
Stable disease	6-10 individuals with IPF 6-10 carers	6-10 individuals with IPF 6-10 carers
n= 48-80		

1  
2  
3 Participants will be purposively sampled [16] to represent the four categories above, based on  
4  
5 their FVC scores contained in their clinical notes, e.g. limited progressive, limited stable,  
6  
7 extensive progressive, extensive stable. Congruent with the recommendations for  
8  
9 Interpretative Phenomenological Analysis (IPA), the sample size for each group will be 6-10  
10  
11 individuals with IPF and 6-10 carers per homogenous group,[17] to represent a perspective  
12  
13 rather than a population. While the total sample size (n=48-80) is therefore large for the  
14  
15 methodology, it is necessary to gain insight into the perspectives of four groups of  
16  
17 participants.  
18  
19

20  
21  
22  
23 Potential participants will be provided with a participant information sheet, reply letter and  
24  
25 stamped addressed envelope by a member of the clinical team in the respiratory clinic, and  
26  
27 requested to return the reply slip to the research team if they are happy to be contacted to take  
28  
29 part in the study. Willing participants will then be telephoned by a researcher and an  
30  
31 interview will be arranged at a time and place convenient for them.  
32  
33

### 34 35 36 Data collection

37  
38 Three data collection methods will be used in this study: recording of demographic and co-  
39  
40 morbidities data, questionnaires and in-depth interviews.  
41  
42

43  
44  
45 *Co-morbidities and demographic data* Demographic variables (age, marital status, location)  
46  
47 and co-morbidities (in particular chronic obstructive pulmonary disease, pulmonary  
48  
49 hypertension and lung cancer) of the individuals with IPF will be recorded by clinicians at the  
50  
51 clinic on a case report form.  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 *Questionnaires* Prior to the in-depth interview, individuals with IPF will be requested to  
4 complete a booklet of questionnaires covering quality of life, anxiety and depression and  
5 symptoms of IPF. These questionnaires will enable the research team to observe whether  
6 quality of life, anxiety and depression change over time and how these correlate with  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

dyspnoea and coughing.

- 1) Quality of life (QOL): a validated, global health-related QOL tool will be used to evaluate quality of life in the form of the EQ-5D, which encompasses five questions on mobility, self-care, usual activities, pain/discomfort and anxiety/depression.[18] Swigris et al. [19] designed and tested a quality of life assessment tool specifically for IPF (ATAQ-IPF), but no other studies were identified that use this tool and therefore we opted for a more generic but well-validated tool.
- 2) Anxiety and depression: the validated Hospital Anxiety and Depression Scale (HADS) includes 14 questions and has been used widely across patient populations and found to be of high specificity and sensitivity.[20]
- 3) Breathlessness: a systematic review [21] found that dyspnoea assessment scales have not been validated for use in palliative care but also identified that the Borg dyspnoea scale, measuring severity of breathlessness on a numerical scale, appeared the most appropriate for use with this population.
- 4) Cough: the Leicester Cough Questionnaire is a 19-item self-completion tool measuring physical, psychological and social quality of life in relation to living with a chronic cough, which demonstrated high specificity and sensitivity.[22] The Cough Symptom Score [23] measures the severity of the cough on a visual analogue scale.

The researcher will assist participants to complete the questionnaires as required, which should take around 20 minutes, and this will occur before the interview to minimise the influence of topics discussed on questionnaire completion.



1  
2  
3  
4  
5 *In-depth interviews* IPA is a qualitative psychological approach used to explore how people  
6  
7 make sense of major events in their lives.[17] Three philosophical approaches influence  
8  
9 IPA:[17] exploring the lived experience (phenomenology); interpretation of the phenomenon  
10  
11 (hermeneutics); exploring the particular rather than attempting to generalise a group  
12  
13 (idiography). This methodology has previously been used successfully to explore palliative  
14  
15 care issues, with both patients [24] and healthcare professionals.[25]  
16  
17  
18  
19

20  
21 To enable access to detailed personal accounts of how participants experience IPF [17], the  
22  
23 research team will utilise semi-structured interviews with people with the disease and their  
24  
25 carers. The interviews will be conducted at a place and time convenient for the participants,  
26  
27 either in their homes or a quiet clinic location, or over the telephone if preferred. One  
28  
29 researcher will conduct the interviews across all sites. It is anticipated that the interviews will  
30  
31 last between 30 and 60 minutes, with the interviewer terminating the discussion if they  
32  
33 become concerned that the participant is unwell or fatigued. We aim to interview individuals  
34  
35 with IPF and carers separately, as is common in qualitative studies with both parties [26,27]  
36  
37 and recommended by Smith et al.[17] If so, relatives will be interviewed first to allow  
38  
39 individuals with IPF to have a break between completing the questionnaire and being  
40  
41 interviewed. However, participants will be interviewed together if they prefer, which Cavers  
42  
43 et al.[28] allowed in their qualitative study due to their participants with glioma struggling at  
44  
45 times with communication. With participants' consent, interviews will be audio-recorded  
46  
47 and transcribed verbatim.  
48  
49  
50

51  
52  
53  
54 An interview schedule will be used (see Table 2) while also enabling participants to influence  
55  
56 the agenda and discuss topics pertinent to them.[17] The interview process is dynamic and  
57  
58  
59  
60

1  
2  
3 iterative and so the schedule will be reviewed after the first few interviews to assess whether  
4  
5 alterations are necessary based on interviewee priorities.  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Table two: interview schedules

<b>Individuals with idiopathic pulmonary fibrosis</b>
<b>Diagnosis</b>
1. What symptoms were you experiencing when you were first diagnosed with IPF? What made you seek medical attention?
2. When and how did you get diagnosed with IPF?
3. Had you heard about the condition before? If yes, what did you know about it?
4. What information were you given about your illness? How useful did you find this information?
5. Did you seek out other information on IPF? If so what, how useful was it?
<b>Living with IPF</b>
6. How does your illness affect you? How has it impacted on your quality of life?
7. How have you been coping with or managing your illness?
8. Which services have you been receiving?
9. What do you think about the support that you have been receiving from health professionals?
10. Are there any gaps in the care that you have been receiving? What else could be done to help you?
<b>The future</b>
11. What is your understanding of how your illness will progress? Do you feel you have enough information about this? What else would you like to know?
12. Do you anticipate the need for more help later on? What kind of help do you think might need?
Is there anything else you've thought of that you would like to mention or discuss now?

**Carers****Diagnosis**

1. When and how did you first learn about (patient's name) illness?
2. What symptoms was (name) experiencing when they were first diagnosed with IPF?  
What made them seek medical attention?
3. Had you heard about the condition before? If yes, what did you know about it?
4. What information were you given about the illness? How useful did you find this information?
5. Did you seek out other information on IPF? If so, what and how useful was it?

**Living with IPF**

6. How does (name) illness affect them?
7. How have they been coping with these changes/ managing their illness?
8. How does (name) illness affect you? How has it impacted on your quality of life?
9. How have you been coping with these changes?
10. Have you been receiving any professional support or assistance?
11. What do you think about the support that you and (name) have been receiving from health professionals?
12. Are there any gaps in the care that (name) has been receiving? What else could be done to help you both?

**The future**

13. What is your understanding of how (name) illness will progress? Do you feel you have enough information about this? What else would you like to know?
14. Do you anticipate the need for more help later on? If so, what kind of help do you think might need?

Is there anything else you've thought of that you would like to mention or discuss now?

## Data analysis

While the quantitative and qualitative data will be analysed separately using appropriate methods, a complementary analysis of both data sets will seek to define key points or triggers for palliative care involvement. This will enable the identification of key components of participants' experiences of the IPF trajectory and clarify what possible interventions could be of benefit to patients and carers.

*Quantitative* The quantitative data will be analysed using SPSS by a member of the research team who is a statistician.

1. Descriptive statistics will be used to present the questionnaire data in graphic format and questionnaire-specific methodologies will be employed.
2. Categorical data will be presented as proportions with a 95% confidence interval (CI) and continuous data as means with a 95% CI. The limited size of the data set means that the analysis will be exploratory.

*Qualitative* IPA data analysis involves considering each case (participant) in turn and systematically interpreting how participants have interpreted their experience, before a narrative account of each case is developed.[17] A six step approach to data analysis is recommended by Smith et al.: [17]

1. Reading and rereading: listening to the interview and reading the transcript to familiarise oneself with the data and ensure that the participant is the focus of the analysis;

2. Initial noting: reading the transcript and noting anything important, including what is said (descriptive), the context of this (linguistic) and identifying patterns in the data and what these mean (conceptual);
3. Developing emerging themes: turning the notes into themes by summarising what is important in the transcript;
4. Connecting themes: this involves mapping how the emergent themes fit together;
5. Moving to the next case: repeating the process with each case, ensuring that each case is treated individually by trying to bracket out the findings from previous cases;
6. Patterns across cases: examining the cases for connections, considering how themes from one case feature in another and which themes are the strongest - redefining themes is common at this stage. The result should be super-ordinate themes and themes within.

The four different groups of participants will be analysed separately with comparison made between the groups. The data will be primarily analysed by the researcher responsible for data collection. Tong et al. [29] recommend research triangulation to promote a deeper understanding of the phenomenon, and therefore 10% of the data will be double coded for agreement by a member second of the research team. Additionally, the research team will confer on the analysis to ensure that there is agreement across the themes.

## **ETHICS AND DISSEMINATION**

### **Ethical considerations**

The study was approved by the university and South East Wales National Health Service Research Ethics Committee in Wales (reference 12/WA/0109) and governance was gained from the three hospital sites in April 2012. The Research Governance Frameworks for

1  
2  
3 England and Wales [30,31] and guidelines from the National Patient Safety Agency [32]  
4  
5 were followed when designing the study.  
6  
7

8  
9  
10 Participants will have a minimum of 24 hours to decide whether to take part in the study and  
11  
12 the research team will ensure that participants are fully aware of the details of the research  
13  
14 prior to collecting written informed consent. Informed consent, which is central to ethical  
15  
16 research,[30] will be taken by the researcher conducting the interview who is experienced at  
17  
18 doing so, or by a member of the clinical team who has undertaken appropriate Good Clinical  
19  
20 Practice (research) training. The research team will ensure that all participants have the  
21  
22 capacity to consent in line with the Mental Capacity Act.[33] All data will be kept strictly  
23  
24 confidential according to the principles of the Data Protection Act [34] and data will be  
25  
26 stored safely in the research unit.  
27  
28

29  
30  
31  
32 There is growing impetus to include patients and the public in health and social care research  
33  
34 as members of the research team, rather than solely as participants, which Tischler et al. [35]  
35  
36 argue encourages the research to be relevant to patients. Therefore, in line with guidance  
37  
38 from Involving People [36] and Involve [37], the study documentation was reviewed by a lay  
39  
40 representative volunteer at the research centre hosting the study. The research centre has a  
41  
42 substantial model of consumer involvement and the nominated study volunteer will be  
43  
44 involved at all stages of the study and will attend regular meetings as a member of the  
45  
46 research team.  
47  
48

### 49 50 51 **Validity and reliability/ rigour**

52  
53  
54 Greene et al. [38] argue that mixed-methods studies enable triangulation of results, thus  
55  
56 increasing confidence in the findings of the research. Thus utilising in-depth interviews and  
57  
58

1  
2  
3 multiple questionnaires to explore participants' quality of life and experience across the  
4  
5 disease trajectory should promote complementarity [38] and deepen interpretations from the  
6  
7 study. Yardley [39] asserts characteristics of "good" qualitative research:  
8

- 9  
10 1. Sensitivity to context: the thorough literature review for this study promotes  
11  
12 sensitivity, which is supported by the clinical and research expertise of the research  
13  
14 team;
- 15  
16 2. Commitment and rigour; transparency and coherence: encouraged through the  
17  
18 proposed systematic and sufficient sampling, experienced qualitative researchers  
19  
20 collecting data and a multidisciplinary team of researchers analysing the data  
21  
22 systematically;
- 23  
24 3. Impact and importance: the objectives of the study are to generate evidence that can  
25  
26 be translated into clinical practice, in particular in relation to the information and  
27  
28 palliative service needs of individuals with IPF and their carers.  
29  
30

31  
32 Furthermore, we aim to promote validity in the use of validated assessment tools with high  
33  
34 specificity and sensitivity.  
35  
36

### 37 38 **Limitations**

39  
40 One limitation of this study is the cross-sectional rather than longitudinal design. However,  
41  
42 as previously discussed, a longitudinal design is extremely challenging and resource intensive  
43  
44 due to the progressive and unpredictable nature of IPF. We believe that the chosen cross-  
45  
46 sectional design will provide representative data in an efficient and inclusive manner.  
47

48  
49 Another limitation is the use of questionnaires that have not been specifically validated for  
50  
51 use with this clinical population. Therefore we have pragmatically selected tools that have  
52  
53 been used successfully with similar groups, are not too onerous for participants to complete  
54  
55  
56  
57



1  
2  
3 and provide a broad perspective of participants' quality of life and provide insight into the  
4  
5 impact of IPF symptoms on everyday life.  
6  
7

### 8 9 **Dissemination**

10 Palliative care research is a developing discipline with significant methodological challenges.  
11  
12 It frequently aims to assess complex interventions in heterogeneous, vulnerable populations.  
13  
14 Successful outcomes depend on robust methodological approaches which are complementary  
15  
16 and which engage multidisciplinary researchers.[40,41] Identifying key points of  
17  
18 intervention and outcomes of importance to patients are essential to both the development of  
19  
20 well-designed pragmatic trials and the implementation of efficient, patient focused clinical  
21  
22 services.  
23  
24  
25  
26  
27

28  
29 There is increasing focus on ensuring that palliative care services are available to and  
30  
31 accessed by individuals with non-malignant diseases – with emphasis on need, not  
32  
33 diagnosis.[42] Idiopathic pulmonary fibrosis is, as previously discussed, an under-researched  
34  
35 disease. We anticipate that the results of this study will provide fundamental information  
36  
37 considering the experiences and needs of individuals and their carers, both quantitatively and  
38  
39 qualitatively, and will therefore be disseminated via relevant clinical and research journals  
40  
41 and international conferences, encompassing both palliative care and respiratory specialities.  
42  
43 The Chief Investigator and three of the Co-Investigators are Consultant Clinicians in  
44  
45 palliative medicine and respiratory specialities, which will enable the planning and provision  
46  
47 of appropriate palliative care services for both individuals with IPF and their carers, across  
48  
49 the illness trajectory. Furthermore, the lay representative involved with the project will be  
50  
51 supported to disseminate the results to relevant patient groups.  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 This paper has explored the incidence and symptoms of idiopathic pulmonary fibrosis, with  
4  
5 discussion of the limited previous research undertaken in this area in terms of quality of life  
6  
7 or experience of the disease. A paucity of research considering the experience and needs of  
8  
9 carers was also identified. This protocol has presented a planned multicentre mixed-methods  
10  
11 study in both England and Wales with people at different stages of IPF and their carers,  
12  
13 utilising validated questionnaires and in-depth interviews. The results of the study may help  
14  
15 healthcare professionals to plan and implement appropriate palliative care services for people  
16  
17 with IPF, and appropriate support for their carers.  
18  
19

#### 20 21 22 23 **Acknowledgment:**

24 We wish to acknowledge the clinical teams who granted access and will support recruitment.  
25  
26  
27

#### 28 29 30 **Competing interests:**

31 None  
32  
33  
34  
35

#### 36 37 **Authors' contributions:**

38 AB is the Chief Investigator, designed the study and reviewed the manuscript. CS contributed  
39  
40 to the protocol, reviewed the manuscript and will collect and analyse data. JB prepared the  
41  
42 manuscript. KH, BHG and RH are site Principal Investigators. GG designed the study. AN  
43  
44 designed the study and reviewed the manuscript.  
45  
46  
47  
48

#### 49 50 **Funding:**

51 This study was funded by a project grant from Marie Curie Cancer Care (reference  
52  
53 C18659/A12565  
54  
55  
56  
57  
58  
59  
60

**REFERENCES**

1. Raghu G, Weycker D, Edelsberg J, Williamson B, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2006;**174**(7):810 - 16
2. Swigris J, Stewart A, Gould M, Wilson S. Patients' perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives. *Health Qual Life Outcomes* 2005;**3**:61 - 69
3. Selman M, King T, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. *Ann Intern Med* 2001;**134**(2):136 - 51
4. Gribbin J, Hubbard R, Le Jeune I, Smith C, West J, Tata L. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. *Thorax* 2006;**61**(11):980 - 85
5. Navaratnam V, Fleming K, West J, et al. The rising incidence of idiopathic pulmonary fibrosis in the UK. *Thorax* 2011;**66**(6):462 - 67
6. Raghu G, Collard H, Egan J, et al., on behalf of the ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. *Am J Respir Crit Care Med* 2011;**183**(6):788 - 824
7. Lee J, McLaughlin S, Collard H. Comprehensive care of the patient with idiopathic pulmonary fibrosis. *Curr Opin Pulm Med* 2011;**17**(5):348 - 54
8. National Institute for Health and Care Excellence. Idiopathic pulmonary fibrosis: diagnosis and management of suspected idiopathic pulmonary fibrosis. <http://www.nice.org.uk/nicemedia/live/14183/64124/64124.pdf>, 2013.
9. World Health Organisation. WHO Definition of Palliative Care. <http://www.who.int/cancer/palliative/definition/en/>, 2012.

- 1  
2  
3 10. World Health Organisation. WHOQOL Measuring Quality of Life.  
4  
5 [http://www.who.int/mental\\_health/media/68.pdf](http://www.who.int/mental_health/media/68.pdf), 1997.  
6
- 7 11. Swigris J, Kuschner W, Jacobs S, Wilson S, Gould M. Health-related quality of life in  
8  
9 patients with idiopathic pulmonary fibrosis: a systematic review. *Thorax* 2005;**60**:558  
10  
11 - 94  
12
- 13 12. Krishnan V, McCormack M, Mathai S, et al. Sleep quality and health-related quality of  
14  
15 life in idiopathic pulmonary disease. *Chest* 2008;**134**(4):693 - 98  
16  
17
- 18 13. Tamioka H, Imanaka K, Hashimoto K, Iwasaki H. Health-related quality of life in  
19  
20 patients with idiopathic pulmonary fibrosis - cross-sectional and longitudinal study.  
21  
22 *Intern Med* 2007;**46**(18):1533 - 42  
23
- 24 14. Scheonheit G, Becattelli I, Cohen A. Living with idiopathic pulmonary fibrosis: an in-  
25  
26 depth qualitative survey of European patients. *Chron Respir Dis* 2011;**8**(4):225 - 31  
27  
28
- 29 15. Bajwah S, Koffman J, Higginson I, et al. 'I wish I knew more...' the end-of-life planning  
30  
31 and information needs for end-stage fibrotic interstitial lung disease: views of  
32  
33 patients, carers and health professionals. *BMJ Support Palliat Care* 2013;**3**:84 - 90  
34  
35
- 36 16. Patton M. *Qualitative Research and Evaluation Methods (3rd edn)*. London: Sage, 2002.  
37
- 38 17. Smith J, Flowers P, Larkin M. *Interpretative Phenomenological Analysis: Theory,*  
39  
40 *Method and Research*. Los Angeles: Sage, 2009: 1 - 232.  
41
- 42 18. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group.  
43  
44 *Annals of Medicine* 2001;**33**(5):337 - 43  
45  
46
- 47 19. Swigris J, Wilson S, Green K, Sprunger D, Brown K, Wamboldt F. Development of the  
48  
49 ATAQ-IPF: a tool to assess quality of life in IPF. *Health Qual Life Outcomes*  
50  
51 2010;**8**:77 - 85  
52  
53
- 54 20. Bjelland I, Dahl A, Haug T, Neckelmann D. The validity of the Hospital Anxiety and  
55  
56 Depression Scale: An updated literature review. *J Psychosom Res* 2002;**52**(2):69 - 77  
57  
58

- 1  
2  
3 21. Dorman S, Byrne A, Edwards A. Which measurement scales should we use to measure  
4  
5 breathlessness in palliative care? A systematic review. *Palliat Med* 2007;**21**(3):177-91  
6  
7  
8 22. Birring S, Prudon B, Carr A, Singh S, Morgan M, Pavord I. Development of a symptom  
9  
10 specific health status measure for patients with chronic cough: Leicester Cough  
11  
12 Questionnaire (LCQ). *Thorax* 2003;**58**(4):339 - 43  
13  
14 23. Jones R, Hilldrup S, Hope-Gill B, Eccles R, Harrison N. Mechanical induction of cough  
15  
16 in Idiopathic Pulmonary Fibrosis. *Cough* 2011;**7**:2 - 12  
17  
18 24. Seamark D, Blake S, Seamark C, Halpin D. Living with severe chronic obstructive  
19  
20 pulmonary disease (COPD): perceptions of patients and their carers: An interpretative  
21  
22 phenomenological analysis. *Palliat Med* 2004;**18**(7):619 - 25  
23  
24  
25 25. Taubert M, Noble S, Nelson A. What challenges good palliative care provision out-of-  
26  
27 hours? A qualitative interview study of out-of-hours general practitioners. *Palliat*  
28  
29 *Med* 2011;**1**:13 - 18  
30  
31  
32 26. Orrevall Y, Tishelman C, Permert J. Home parenteral nutrition: A qualitative interview  
33  
34 study of the experiences of advanced cancer patients and their families. *Clin Nutr*  
35  
36 2005;**24**(6):961 - 70  
37  
38  
39 27. White Y, Grenyer B. The biopsychosocial impact of end-stage renal disease: the  
40  
41 experience of dialysis patients and their partners. *J Adv Nurs* 1999;**30**(6):1312 - 29  
42  
43 28. Cavers D, Hacking B, Erridge S, Morris P, Kendall M, Murray S. Adjustment and support  
44  
45 needs of glioma patients and their relatives: serial interviews. *Psychooncology*  
46  
47 2012;**DOI 10.1002/pon.3136**.  
48  
49 29. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research  
50  
51 (COREQ): a 32-item checklist for interviews and focus groups. *Int J Qual Health Care*  
52  
53 2007;**19**(6):349 - 57  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 30. Department of Health. Research Governance Framework for Health and Social Care (2nd  
4  
5 edn.).  
6  
7 [http://www.dh.gov.uk/prod\\_consum\\_dh/groups/dh\\_digitalassets/@dh/@en/document](http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4122427.pdf)  
8  
9 [s/digitalasset/dh\\_4122427.pdf](http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4122427.pdf) 2005.  
10  
11  
12 31. Welsh Assembly Government. Research Governance Framework for Health and Social  
13  
14 Care in Wales (2nd ed.).  
15  
16 [http://cymru.gov.uk/topics/health/research/word/publications/researchgovernance/?lan](http://cymru.gov.uk/topics/health/research/word/publications/researchgovernance/?lang=en)  
17  
18 [g=en](http://cymru.gov.uk/topics/health/research/word/publications/researchgovernance/?lang=en)] 2009.  
19  
20  
21 32. National Patient Safety Agency. Information Sheets and Consent Forms: Guidance for  
22  
23 Researchers and Reviewers.  
24  
25 [www.nres.nhs.uk/EasySiteWeb/GatewayLink.aspx?allId=338](http://www.nres.nhs.uk/EasySiteWeb/GatewayLink.aspx?allId=338), 2011.  
26  
27  
28 33. United Kingdom. Mental Capacity Act 2005.  
29  
30 [http://www.opsi.gov.uk/acts/acts2005/ukpga\\_20050009\\_en\\_1](http://www.opsi.gov.uk/acts/acts2005/ukpga_20050009_en_1) 2005.  
31  
32 34. United Kingdom. Data Protection Act 1998.  
33  
34 [http://www.opsi.gov.uk/acts/acts1998/ukpga\\_19980029\\_en\\_1](http://www.opsi.gov.uk/acts/acts1998/ukpga_19980029_en_1) 1998.  
35  
36 35. Tischler V, D'Silva K, Cheetham A, Goring M, Calton T. Involving patients in research:  
37  
38 the challenge of patient-centredness. *Int J Soc Psychiatry* 2010;**56**(6):623 - 33  
39  
40  
41 36. Moore B, Porteous C, Simon N. Pathways for Involving People in Social Care and Health  
42  
43 Research in Wales: A Signposting Document. <http://www.involvingpeople.org.uk/>],  
44  
45 2007.  
46  
47 37. Vale C, Fitzgibbon J, Hanley B, et al. Public involvement in clinical trials: Supplement to  
48  
49 the briefing notes for researchers. [http://www.invo.org.uk/wp-](http://www.invo.org.uk/wp-content/uploads/2012/04/INVOLVEpublicinvolvementinclinicaltrialsBriefingnotes2012.pdf)  
50  
51 [content/uploads/2012/04/INVOLVEpublicinvolvementinclinicaltrialsBriefingnotes20](http://www.invo.org.uk/wp-content/uploads/2012/04/INVOLVEpublicinvolvementinclinicaltrialsBriefingnotes2012.pdf)  
52  
53 [12.pdf](http://www.invo.org.uk/wp-content/uploads/2012/04/INVOLVEpublicinvolvementinclinicaltrialsBriefingnotes2012.pdf), 2012.  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 38. Greene J, Caracelli V, Graham W. Toward a conceptual framework for mixed-method  
4  
5 evaluation designs. *Education Evaluation and Policy Analysis* 1989;**11**(3):255 - 74  
6  
7  
8 39. Yardley L. Dilemmas in qualitative health research. *Psychology and Health*  
9  
10 2000;**15**(2):215 - 28  
11  
12 40. Byrne A, Hood K, Griffiths G, Maughan T. Design and conduct of research and clinical  
13  
14 trials. In: Walsh D, Caraceni A, Fainsinger R, et al., eds. *Palliative Medicine*.  
15  
16 Philadelphia: Saunders Elsevier, 2009.  
17  
18 41. Kaasa S, Hjermstad M, Loge J. Methodological and structural challenges in palliative  
19  
20 care research: how have we fared in the last decades? *Palliat Med* 2006;**20**(8):727 - 34  
21  
22  
23 42. Fallon M, Foley P. Rising to the challenge of palliative care for non-malignant disease.  
24  
25 *Palliat Med* 2012;**26**(2):99 - 100  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Full title:**

A mixed-methods study of the ~~care~~-Care Needs of individuals with idiopathic Pulmonary fibrosis and their carers: CaNoPy. A study protocol.

**Short title:**

Care needs of individuals with idiopathic pulmonary fibrosis and their carers

**Author details:**

Anthony Byrne – corresponding author

Consultant in Palliative Medicine, Cardiff and Vale University Health Board

Director, Marie Curie Palliative Care Research Centre, Wales Cancer Trials Unit, Cardiff

University School of Medicine

6<sup>th</sup> Floor Neuadd Meirionnydd

Heath Park

Cardiff CF14 4YS

[Anthony.Byrne2@wales.nhs.uk](mailto:Anthony.Byrne2@wales.nhs.uk)

02920 687175

Cathy Sampson

Research Associate, Marie Curie Palliative Care Research Centre, Wales Cancer Trials Unit,

Cardiff University School of Medicine

[SampsonC2@cf.ac.uk](mailto:SampsonC2@cf.ac.uk)

Jessica Baillie



1  
2  
3 Research Associate, Marie Curie Palliative Care Research Centre, Wales Cancer Trials Unit,  
4  
5 Cardiff University School of Medicine  
6  
7 BaillieJ4@cf.ac.uk  
8  
9

10  
11  
12 Kim Harrison  
13  
14 Consultant Physician, Abertawe Bro Morgannwg University Health Board  
15  
16 Kim.Harrison@wales.nhs.uk  
17  
18

19  
20  
21 Ben Hope-Gill  
22  
23 Consultant Physician, Cardiff and Vale University Health Board  
24  
25 Ben.Hope-gill@wales.nhs.uk  
26  
27

28  
29  
30 Richard Hubbard  
31  
32 Professor of Respiratory Medicine, Nottingham City Hospital  
33  
34 GSK/British Lung Foundation Professor of Respiratory Epidemiology, Faculty of Medicine  
35  
36 & Health Sciences, University of Nottingham  
37  
38 Richard.hubbard@nottingham.ac.uk  
39  
40

41  
42  
43 Gareth Griffiths  
44  
45 Director, Wales Cancer Trials Unit, Cardiff University School of Medicine  
46  
47 GriffithsG@cf.ac.uk  
48  
49

50  
51  
52 Annmarie Nelson  
53  
54 Deputy Director, Marie Curie Palliative Care Research Centre, Wales Cancer Trials Unit,  
55  
56 Cardiff University School of Medicine  
57  
58  
59  
60

NelsonA9@cf.ac.uk

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Introduction** Idiopathic pulmonary fibrosis (IPF) is a progressive, life threatening illness of unknown aetiology, with no proven pharmacological treatments. There is a limited evidence base indicating that the disease negatively affects quality of life, leading to increased dependence, restrictions on daily activities and fatigue. However, there is a paucity of in-depth information on disease impact across its trajectory, particularly in relation to unmet needs, outcomes of importance to patients and the experiences of carers. Furthermore, little is known about the support and information needs of individuals and their carers, or at what point individual need should trigger a referral to palliative care services.

**Methods and analysis** A mixed-methods study is proposed recruiting individuals with IPF at different stages of the disease and their carers from three respiratory centres in England and Wales. In-depth interviews will be undertaken with participants adopting an Interpretative Phenomenological Analysis approach. The study will also use validated questionnaires to explore quality of life (EQ-5D), depression (Hospital Anxiety and Depression Scale), breathlessness (Borg dyspnoea scale) and cough (Leicester Cough Questionnaire, Cough Symptom Score).

**Ethics and dissemination** Ethical approvals were gained in April 2012. Palliative care research is a developing field, but there has been limited focus on idiopathic pulmonary fibrosis. We anticipate that the results of the study will enable healthcare professionals to provide appropriate palliative care across the trajectory for individuals with the disease, and their carers, and we therefore aim to disseminate via relevant respiratory and palliative care

1  
2  
3 journals and conferences. We will also support the lay representative involved in the project  
4  
5 to disseminate the findings to patient groups.  
6  
7

8  
9 **KEYWORDS**

10 Idiopathic pulmonary fibrosis, carer, mixed-methods, Interpretative Phenomenological  
11  
12 Analysis  
13  
14

15  
16  
17  
18 **WORD COUNT**

19  
20  
21 | 4,339  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ARTICLE SUMMARY

### Article focus

- Idiopathic pulmonary fibrosis is a progressive, life threatening illness with high symptom burden. However there has been very limited research into patient perception of need, carer burden or patient/carer defined outcomes of importance in this population;
- A cross-sectional mixed-method study is proposed to explore the experiences and needs of individuals and their carers across the illness trajectory of idiopathic pulmonary fibrosis.

### Key messages

- The findings from this study should influence the care provided across the illness trajectory, particularly in terms of the information needs of individuals and carers at different stages of the disease, and identification of triggers for palliative care service involvement;
- The study will also determine outcomes of importance to patients which might influence both clinical service evaluation and the design of future interventional studies in IPF.

### Strengths and limitations of this study

- While this study is cross-sectional, rather than longitudinal, a large sample of patients at differences stages of the disease, and their relatives, will be included;
- This multi-centre study, in both England and Wales, will also adopt a mixed-methods approach, including qualitative interviews and the use of validated questionnaires.

## INTRODUCTION

Idiopathic pulmonary fibrosis (IPF) is a progressive, life-limiting condition characterised by chronic inflammation and scarring,[1] causing breathlessness and a dry cough in the individual.[2] The aetiology of IPF is unknown and the disease is progressive.[3] The illness trajectory of IPF is variable and a study from the United Kingdom (UK) found that individuals lived with the disease for a median of three years before death,[4] which is usually due to respiratory failure.[2] Identifying the prevalence of IPF is challenging as no mandatory monitoring register exists, but the overall incidence in the UK is 7.44 per 100,000, with more men and older people affected.[5] While anti-inflammatory, immunosuppressant and anti-fibrotic medications are prescribed for IPF;[1] no pharmacologic treatments are proven to treat IPF,[6] with the only significant treatment intervention being lung transplantation.

Lee et al. [7] describe a holistic approach to care for individuals with IPF, including: disease-management (including medications), promoting education and self-management, and symptom management. They further assert that palliative care should be fundamental and central to the management of IPF,[7] which has been similarly encouraged in recent clinical guidance from the National Institute for Health and Care Excellence (NICE) in the UK.[8]

Palliative care is defined by the World Health Organisation [9] as:

“an approach that improves the quality of life of patients and their families facing the problem associated with life-threatening illness, through the prevention and relief of suffering by means of early identification and impeccable assessment and treatment of pain and other problems, physical, psychosocial and spiritual”

However, there is a paucity of research considering at what stage palliative care should be offered to individuals with IPF, and what care and support patients feel would benefit them.

1  
2  
3  
4  
5 This protocol therefore describes a proposed cross-sectional mixed-methods study ([CaNoPy: Care Needs of individuals with idiopathic Pulmonary fibrosis and their carers](#)) designed to  
6  
7  
8  
9 investigate the needs and experiences of individuals with idiopathic pulmonary fibrosis, and  
10  
11 their carers across, the illness trajectory.  
12  
13

### 14 15 16 **Literature review**

17  
18 A literature search was undertaken using MEDLINE, CINAHL and PubMed, with additional  
19  
20 hand-searching of reference lists, to identify individuals' and carers' experiences of IPF and  
21  
22 the impact of the disease on their quality of life. The search identified several studies  
23  
24 considering quality of life for individuals with IPF, but fewer studies used a qualitative  
25  
26 approach to explore their experiences of the disease. A dearth of studies focussing on the  
27  
28 experiences of carers/ family members is also noted.  
29  
30  
31

### 32 33 34 **Quality of life and IPF**

35  
36 The World Health Organisation [10] define quality of life as an individual's "perception of  
37  
38 their position in life in the context of the culture and value systems in which they live and in  
39  
40 relation to their goals, expectations, standards and concerns" (p.7). Furthermore, Swigris et  
41  
42 al. [11] assert that health-related quality of life is an individual's "perception of the impact of  
43  
44 health (in all its many facets) on his or her quality of life" (p.588). A systematic review by  
45  
46 Swigris et al. [11] revealed that a small number of studies consider the quality of life of  
47  
48 individuals with IPF. After a methodical literature search, Swigris et al. [11] identified only  
49  
50 seven studies that assessed quality of life in a total of 512 adults with IPF. The included  
51  
52 studies, which used the Medical Outcomes Study Short-Form 36-item tool (SF-36), World  
53  
54 Health Organisation Quality of Life 100-item tool (WHO-QOL) or the St George's  
55  
56  
57  
58  
59  
60

1  
2  
3 Respiratory Questionnaire (SGRQ), were conducted in Japan, the Netherlands, Brazil and the  
4  
5 United States of America (USA).[11] Health-related quality of life was found to be  
6  
7 significantly lower than the general population in almost all domains, but particularly  
8  
9 physical aspects such as respiratory symptoms, energy levels and degrees of  
10  
11 independence.[11] Specifically, dyspnoea was associated with worse quality of life.[11]  
12  
13

14  
15  
16 More recent studies considering quality of life have been identified since Swigris et al.'s [11]  
17  
18 systematic review. An American cross-sectional study of 41 adults with IPF assessed fatigue,  
19  
20 sleep quality and quality of life with validated tools: Pittsburgh sleep quality index, Epworth  
21  
22 sleepiness scale and the SF-36.[12] Participants in Krishnan et al.'s [12] study reported  
23  
24 significantly poorer sleep than the general population, and like Swigris et al. [11] identified  
25  
26 that quality of life was significantly reduced in most domains, in particular physical aspects.  
27  
28 Additionally, sleep quality was associated with reduced quality of life, which included  
29  
30 physical and emotional measures,[12] and the authors thus recommend interventions to  
31  
32 improve sleep quality. Few studies have adopted longitudinal approaches when considering  
33  
34 quality of life in people with IPF. However, Tomioka et al. [13] adopted a cross-sectional  
35  
36 and longitudinal approach, measuring quality of life using the SF-36 at baseline (n=46) and  
37  
38 again at least 12 months later (n=32) for participants who had not died, developed other  
39  
40 major diseases or lost to follow-up. At baseline, participants reported significantly reduced  
41  
42 quality of life compared to the general population, while quality of life had worsened  
43  
44 significantly longitudinally in terms of physical function and bodily pain.[13]  
45  
46  
47  
48  
49  
50

51  
52 The small number of studies assessing the quality of life of people with IPF thus highlights  
53  
54 significantly reduced outcomes, in particular in terms of physical health and sleep quality.  
55

56 However, no studies were identified that quantitatively measured relatives' or carers' quality  
57  
58  
59  
60



1  
2  
3 of life when caring for an individual with this progressive, terminal disease. Nor have they  
4  
5 explored in detail the experiences underlying quality of life deterioration or patient/carer  
6  
7 perceptions of interventions which might alter outcomes of importance. Of particular interest  
8  
9 given the variable trajectory of the disease, is the identification of triggers for supportive and  
10  
11 palliative interventions.  
12

### 13 14 15 16 Qualitative experiences of IPF

17  
18 Three studies were identified that explore the experiences of individuals with IPF using  
19  
20 qualitative methods; although none of the studies discuss their methodological or  
21  
22 philosophical approaches. Additionally, the papers do not discuss participants' disease  
23  
24 stages.  
25  
26

27  
28  
29 Swigris et al. [2] undertook focus groups or individual interviews with 20 adults living with  
30  
31 IPF in the USA. The purpose of the study was to develop an IPF-sensitive health related  
32  
33 quality of life measure by comparing the findings of the study to commonly-used global or  
34  
35 respiratory tools. Dyspnoea and coughing were found to be distressing and impaired quality  
36  
37 of life, medications for IPF caused significant side-effects, sleep quality was affected, low  
38  
39 energy or exhaustion affected daily activities, forward planning was necessary and  
40  
41 employment was either impossible or for some necessary to pay for medical care.[2]  
42  
43 Furthermore, participants were concerned about being a physical or financial burden,  
44  
45 appreciation was expressed towards relatives, IPF led to decreased libido or inability to  
46  
47 undertake sexual activity, social activities were limited, and participants were fearful about  
48  
49 their health and recognised their mortality.[2] The authors concluded that an IPF-specific  
50  
51 quality of life instrument is required as their participants' perspectives of the disease were not  
52  
53 sufficiently reflected in generic tools.  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 Schoenheit et al. [14] undertook single in-depth interviews with 45 adults with IPF, from five  
6  
7 European countries: Spain, Italy, UK, France and Germany. Additionally, 18 relatives were  
8  
9 present during the interviews, although the article provides little insight into their  
10  
11 experiences. The authors used psychological techniques of asking participants to select  
12  
13 images that express their feelings and asking them to recall what was said in a particular  
14  
15 situation. The study also collated details of symptoms and revealed that dyspnoea was  
16  
17 experienced by 68% of participants, 59% reported a cough and 28% reported fatigue.[14]  
18  
19  
20 The majority of participants had experienced delayed diagnoses and criticised the care they  
21  
22 received, while the minority of participants who were diagnosed promptly reported their care  
23  
24 more positively.[14] Both groups, however, reported rushed and insensitive diagnosis and a  
25  
26 lack of available information to them about the disease. IPF was found to have a substantial  
27  
28 impact on daily life in terms of reduced independence, difficulty in continuing relationships  
29  
30 and struggling financially through being unable to work.[14]  
31  
32  
33  
34  
35

36 More recently, Bajwah et al. [15] interviewed eight patients with IPF, four carers (related to  
37  
38 different patients) and six healthcare professionals in the UK. They highlighted that patients  
39  
40 and carers had limited understanding of the disease, which made it difficult to plan ahead,  
41  
42 and that patients had not discussed end of life preferences.[15] While patients and carers  
43  
44 reported feeling satisfied with the care provided by the respiratory team, they also reported a  
45  
46 lack of coordination between different healthcare professionals and teams.[15]  
47  
48  
49  
50

51 IPF thus has a broad negative impact on everyday life for the individual, particularly in terms  
52  
53 of increased dependence on relatives, reduction in socialising, financial concerns, recognition  
54  
55 of mortality and a dearth of information. Bajwah et al. [15] included a small sample of carers  
56  
57  
58  
59  
60

1  
2  
3 but do not explicate their needs while caring for an individual with IPF, while Schoenheit et  
4 al.'s [14] study included relatives but the authors make little reference to them in their paper.  
5  
6  
7 Therefore, additional studies are required to understand carer experiences of IPF and what  
8  
9 support they require to care for a relative with the condition. Interrogating the experiences of  
10  
11 carers, and their needs, is crucial in a condition that is terminal and will thus require a high  
12  
13 level of support from those closest to the individual with IPF.  
14  
15

16  
17  
18 This protocol thus presents a study designed to explore the perspectives of both the individual  
19  
20 with IPF and their carer, at different stages of the disease.  
21  
22  
23

## 24 25 26 27 **METHODS**

### 28 29 30 31 **Aim and objectives**

32  
33  
34 Aim: The aim of this study is to explore the needs of individuals with IPF and their families  
35  
36 across the illness trajectory.  
37  
38

#### 39 40 41 Objectives:

- 42  
43 1) Identify changes in individuals' and carers' perceived palliative care needs over the  
44  
45 progression of IPF in order to improve future service interventions;  
46
- 47  
48 2) Identify time-points or triggers at which palliative care services might effectively be  
49  
50 introduced;  
51
- 52  
53 3) Define the specific information needs of individuals and their carers;  
54
- 55  
56 4) Evaluate specifically the experiences and roles of the carer.  
57  
58  
59  
60

## Methodology and methods

The uncertain nature of disease progression makes a longitudinal study difficult to achieve in a set time frame and therefore a cross-sectional design with individuals at different stages of the IPF trajectory was chosen. To meet the aim and objectives of the study, a mixed-methods approach will be undertaken, encompassing the use of validated assessment tools (quality of life, anxiety and depression, and IPF symptoms) and in-depth interviews utilising Interpretive Phenomenological Analysis (IPA) methodology. Participants will be recruited and data collected from three National Health Service (NHS) respiratory centres, including two Health Boards within Wales and one NHS Trust in England.

### Recruitment and sampling

Individuals with IPF and their carers (a person of their choice who contributes most to their care, or at an earlier disease stage provides emotional support) will be recruited from the three respiratory centres, where a member of the clinical team will provide them with information about the study. Eligibility for the study will be decided by the clinical team according to a study proforma, which classifies individuals at different stages on the IPF trajectory and documents respiratory co-morbidities.

The inclusion criteria for individuals will be a diagnosis of IPF and receiving medical care for IPF at one of the three centres, the ability to give informed consent to communicate sufficiently to take part in an interview. The inclusion criteria for carers include caring for an individual with IPF in the study, ability to give informed consent and communicate adequately to be interviewed. The exclusion criteria for individuals with IPF and carers will be any factor that prevents communication or comprehension. A disease typology was generated by palliative and respiratory consultants who are part of the research team to

1  
2  
3 classify four different stages of the disease. To provide an insight into individuals', and thus  
4  
5 carers', needs across the disease trajectory, four groups of participants (see table 1) will be  
6  
7 recruited, including people with:

- 10 1. Limited disease: forced vital capacity (FVC) greater than 50% predicted and gas  
11 transfer (TLCO) greater than 40% predicted;
- 14 2. Extensive disease: FVC less than 50% or TLCO less than 40% predicted;
- 16 3. Progressive disease: a fall in either FVC greater than 10% or TLCO greater than 15%  
17 during the previous 12 months;
- 20 4. Stable disease: a fall of less than 10% in FVC or less than 15% in TLCO in the  
21 previous 12 months.

27 Table one: participant group characteristics

30 <b>Participant group and</b>	Limited disease	Extensive disease
31 <b>characteristics</b>		
34 Progressive disease	6-10 individuals with IPF 6-10 carers	6-10 individuals with IPF 6-10 carers
39 Stable disease	6-10 individuals with IPF 6-10 carers	6-10 individuals with IPF 6-10 carers
44 n= 48-80		

46  
47  
48  
49 Participants will be purposively sampled [16] to represent the four categories above, based on  
50 their FVC scores contained in their clinical notes, e.g. limited progressive, limited stable,  
51  
52 extensive progressive, extensive stable. Congruent with the recommendations for  
53  
54 Interpretative Phenomenological Analysis (IPA), the sample size for each group will be 6-10  
55  
56  
57

1  
2  
3 individuals with IPF and 6-10 carers per homogenous group,[17] to represent a perspective  
4  
5 rather than a population. While the total sample size (n=48-80) is therefore large for the  
6  
7 methodology, it is necessary to gain insight into the perspectives of four groups of  
8  
9 participants.  
10

11  
12  
13  
14 Potential participants will be provided with a participant information sheet, reply letter and  
15  
16 stamped addressed envelope by a member of the clinical team in the respiratory clinic, and  
17  
18 requested to return the reply slip to the research team if they are happy to be contacted to take  
19  
20 part in the study. Willing participants will then be telephoned by a researcher and an  
21  
22 interview will be arranged at a time and place convenient for them.  
23  
24

#### 25 26 27 Data collection

28  
29 Three data collection methods will be used in this study: recording of demographic and co-  
30  
31 morbidities data, questionnaires and in-depth interviews.  
32  
33

34  
35  
36 *Co-morbidities and demographic data* Demographic variables (age, marital status, location)  
37  
38 and co-morbidities (in particular chronic obstructive pulmonary disease, pulmonary  
39  
40 hypertension and lung cancer) of the individuals with IPF will be recorded by clinicians at the  
41  
42 clinic on a case report form.  
43  
44

45  
46  
47 *Questionnaires* Prior to the in-depth interview, individuals with IPF will be requested to  
48  
49 complete a booklet of questionnaires covering quality of life, anxiety and depression and  
50  
51 symptoms of IPF. These questionnaires will enable the research team to observe whether  
52  
53 quality of life, anxiety and depression change over time and how these correlate with  
54  
55 dyspnoea and coughing.  
56  
57

- 1) Quality of life (QOL): a validated, global health-related QOL tool will be used to evaluate quality of life in the form of the EQ-5D, which encompasses five questions on mobility, self-care, usual activities, pain/discomfort and anxiety/depression.[18] Swigris et al. [19] designed and tested a quality of life assessment tool specifically for IPF (ATAQ-IPF), but no other studies were identified that use this tool and therefore we opted for a more generic but well-validated tool.
- 2) Anxiety and depression: the validated Hospital Anxiety and Depression Scale (HADS) includes 14 questions and has been used widely across patient populations and found to be of high specificity and sensitivity.[20]
- 3) Breathlessness: a systematic review [21] found that dyspnoea assessment scales have not been validated for use in palliative care but also identified that the Borg dyspnoea scale, measuring severity of breathlessness on a numerical scale, appeared the most appropriate for use with this population.
- 4) Cough: the Leicester Cough Questionnaire is a 19-item self-completion tool measuring physical, psychological and social quality of life in relation to living with a chronic cough, which demonstrated high specificity and sensitivity.[22] The Cough Symptom Score [23] measures the severity of the cough on a visual analogue scale.

The researcher will assist participants to complete the questionnaires as required, which should take around 20 minutes, and this will occur before the interview to minimise the influence of topics discussed on questionnaire completion.

*In-depth interviews* IPA is ~~as~~ a qualitative psychological approach used to explore how people make sense of major events in their lives.[17] Three philosophical approaches influence IPA:[17] exploring the lived experience (phenomenology); interpretation of the phenomenon (hermeneutics); exploring the particular rather than attempting to generalise a

1  
2  
3 group (idiography). This methodology has previously been used successfully to explore  
4  
5 palliative care issues, with both patients [24] and healthcare professionals.[25]  
6  
7

8  
9  
10 To enable access to detailed personal accounts of how participants experience IPF [17], the  
11  
12 research team will utilise semi-structured interviews with people with the disease and their  
13  
14 carers. The interviews will be conducted at a place and time convenient for the participants,  
15  
16 either in their homes or a quiet clinic location, or over the telephone if preferred. One  
17  
18 researcher will conduct the interviews across all sites. It is anticipated that the interviews will  
19  
20 last between 30 and 60 minutes, with the interviewer terminating the discussion if they  
21  
22 become concerned that the participant is unwell or fatigued. We aim to interview individuals  
23  
24 with IPF and carers separately, as is common in qualitative studies with both parties [26,27]  
25  
26 and recommended by Smith et al.[17] If so, relatives will be interviewed first to allow  
27  
28 individuals with IPF to have a break between completing the questionnaire and being  
29  
30 interviewed. However, participants will be interviewed together if they prefer, which Cavers  
31  
32 et al.[28] allowed in their qualitative study due to their participants with glioma struggling at  
33  
34 times with communication. With participants' consent, interviews will be audio-recorded  
35  
36 and transcribed verbatim.  
37  
38  
39  
40  
41  
42

43 An interview schedule will be used (see Table 2) while also enabling participants to influence  
44  
45 the agenda and discuss topics pertinent to them.[17] The interview process is dynamic and  
46  
47 iterative and so the schedule will be reviewed after the first few interviews to assess whether  
48  
49 alterations are necessary based on interviewee priorities.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



Table two: interview schedules

<b>Individuals with idiopathic pulmonary fibrosis</b>
<b>Diagnosis</b>
1. What symptoms were you experiencing when you were first diagnosed with IPF? What made you seek medical attention?
2. When and how did you get diagnosed with IPF?
3. Had you heard about the condition before? If yes, what did you know about it?
4. What information were you given about your illness? How useful did you find this information?
5. Did you seek out other information on IPF? If so what, how useful was it?
<b>Living with IPF</b>
6. How does your illness affect you? How has it impacted on your quality of life?
7. How have you been coping with or managing your illness?
8. Which services have you been receiving?
9. What do you think about the support that you have been receiving from health professionals?
10. Are there any gaps in the care that you have been receiving? What else could be done to help you?
<b>The future</b>
11. What is your understanding of how your illness will progress? Do you feel you have enough information about this? What else would you like to know?
12. Do you anticipate the need for more help later on? What kind of help do you think might need?
Is there anything else you've thought of that you would like to mention or discuss now?

**Carers****Diagnosis**

1. When and how did you first learn about (patient's name) illness?
2. What symptoms was (name) experiencing when they were first diagnosed with IPF?  
What made them seek medical attention?
3. Had you heard about the condition before? If yes, what did you know about it?
4. What information were you given about the illness? How useful did you find this information?
5. Did you seek out other information on IPF? If so, what and how useful was it?

**Living with IPF**

6. How does (name) illness affect them?
7. How have they been coping with these changes/ managing their illness?
8. How does (name) illness affect you? How has it impacted on your quality of life?
9. How have you been coping with these changes?
10. Have you been receiving any professional support or assistance?
11. What do you think about the support that you and (name) have been receiving from health professionals?
12. Are there any gaps in the care that (name) has been receiving? What else could be done to help you both?

**The future**

13. What is your understanding of how (name) illness will progress? Do you feel you have enough information about this? What else would you like to know?
14. Do you anticipate the need for more help later on? If so, what kind of help do you think might need?

1  
2  
3 Is there anything else you've thought of that you would like to mention or discuss now?  
4  
5  
6

7  
8 Data analysis

9  
10 While the quantitative and qualitative data will be analysed separately using appropriate  
11 methods, a complementary analysis of both data sets will seek to define key points or triggers  
12 for palliative care involvement. This will enable the identification of key components of  
13 participants' experiences of the IPF trajectory and clarify what possible interventions could  
14 be of benefit to patients and carers.  
15  
16  
17  
18  
19  
20

21  
22  
23 *Quantitative* The quantitative data will be analysed using SPSS by a member of the research  
24 team who is a statistician.  
25  
26

- 27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39
1. Descriptive statistics will be used to present the questionnaire data in graphic format and questionnaire-specific methodologies will be employed.
  2. Categorical data will be presented as proportions with a 95% confidence interval (CI) and continuous data as means with a 95% CI. The limited size of the data set means that the analysis will be exploratory.

40  
41  
42  
43  
44  
45  
46  
47  
48  
49

*Qualitative* IPA data analysis involves considering each case (participant) in turn and systematically interpreting how participants have interpreted their experience, before a narrative account of each case is developed.[17] A six step approach to data analysis is recommended by Smith et al.: [17]

- 50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
1. Reading and rereading: listening to the interview and reading the transcript to familiarise oneself with the data and ensure that the participant is the focus of the analysis;

2. Initial noting: reading the transcript and noting anything important, including what is said (descriptive), the context of this (linguistic) and identifying patterns in the data and what these mean (conceptual);
3. Developing emerging themes: turning the notes into themes by summarising what is important in the transcript;
4. Connecting themes: this involves mapping how the emergent themes fit together;
5. Moving to the next case: repeating the process with each case, ensuring that each case is treated individually by trying to bracket out the findings from previous cases;
6. Patterns across cases: examining the cases for connections, considering how themes from one case feature in another and which themes are the strongest - redefining themes is common at this stage. The result should be super-ordinate themes and themes within.

The four different groups of participants will be analysed separately with comparison made between the groups. The data will be primarily analysed by the researcher responsible for data collection. Tong et al. [29] recommend research triangulation to promote a deeper understanding of the phenomenon, and therefore 10% of the data will be double coded for agreement by a member second of the research team. Additionally, the research team will confer on the analysis to ensure that there is agreement across the themes.

## ETHICS AND DISSEMINATION

### Ethical considerations

The study was approved by the university and regional-South East Wales National Health Service Research Ethics Committee in Wales (reference 12/WA/0109) and governance was gained from the three hospital sites in April 2012. The Research Governance Frameworks

1  
2  
3 for England and Wales [30,31] and guidelines from the National Patient Safety Agency [32]  
4  
5 were followed when designing the study.  
6  
7

8  
9  
10 Participants will have a minimum of 24 hours to decide whether to take part in the study and  
11  
12 the research team will ensure that participants are fully aware of the details of the research  
13  
14 prior to collecting written informed consent. Informed consent, which is central to ethical  
15  
16 research,[30] will be taken by the researcher conducting the interview who is experienced at  
17  
18 doing so, or by a member of the clinical team who has undertaken appropriate Good Clinical  
19  
20 Practice (research) training. The research team will ensure that all participants have the  
21  
22 capacity to consent in line with the Mental Capacity Act.[33] All data will be kept strictly  
23  
24 confidential according to the principles of the Data Protection Act [34] and data will be  
25  
26 stored safely in the research unit.  
27  
28

29  
30  
31  
32 There is growing impetus to include patients and the public in health and social care research  
33  
34 as members of the research team, rather than solely as participants, which Tischler et al. [35]  
35  
36 argue encourages the research to be relevant to patients. Therefore, in line with guidance  
37  
38 from Involving People [36] and Involve [37], the study documentation was reviewed by a lay  
39  
40 representative volunteer at the research centre hosting the study. The research centre has a  
41  
42 substantial model of consumer involvement and the nominated study volunteer will be  
43  
44 involved at all stages of the study and will attend regular meetings as a member of the  
45  
46 research team.  
47  
48

### 49 50 51 **Validity and reliability/ rigour**

52  
53  
54 Greene et al. [38] argue that mixed-methods studies enable triangulation of results, thus  
55  
56 increasing confidence in the findings of the research. Thus utilising in-depth interviews and  
57  
58

1  
2  
3 multiple questionnaires to explore participants' quality of life and experience across the  
4  
5 disease trajectory should promote complementarity [38] and deepen interpretations from the  
6  
7 study. Yardley [39] asserts characteristics of "good" qualitative research:  
8

- 9  
10 1. Sensitivity to context: the thorough literature review for this study promotes  
11  
12 sensitivity, which is supported by the clinical and research expertise of the research  
13  
14 team;
- 15  
16 2. Commitment and rigour; transparency and coherence: encouraged through the  
17  
18 proposed systematic and sufficient sampling, experienced qualitative researchers  
19  
20 collecting data and a multidisciplinary team of researchers analysing the data  
21  
22 systematically;
- 23  
24 3. Impact and importance: the objectives of the study are to generate evidence that can  
25  
26 be translated into clinical practice, in particular in relation to the information and  
27  
28 palliative service needs of individuals with IPF and their carers.  
29  
30

31  
32 Furthermore, we aim to promote validity in the use of validated assessment tools with high  
33  
34 specificity and sensitivity.  
35  
36

### 37 38 **Limitations**

39  
40 One limitation of this study is the cross-sectional rather than longitudinal design. However,  
41  
42 as previously discussed, a longitudinal design is extremely challenging and resource intensive  
43  
44 due to the progressive and unpredictable nature of IPF. We believe that the chosen cross-  
45  
46 sectional design will provide representative data in an efficient and inclusive manner.  
47

48  
49 Another limitation is the use of questionnaires that have not been specifically validated for  
50  
51 use with this clinical population. Therefore we have pragmatically selected tools that have  
52  
53 been used successfully with similar groups, are not too onerous for participants to complete  
54  
55  
56  
57

1  
2  
3 and provide a broad perspective of participants' quality of life and provide insight into the  
4  
5 impact of IPF symptoms on everyday life.  
6  
7

### 8 9 **Dissemination**

10 Palliative care research is a developing discipline with significant methodological challenges.  
11  
12 It frequently aims to assess complex interventions in heterogeneous, vulnerable populations.  
13  
14 Successful outcomes depend on robust methodological approaches which are complementary  
15  
16 and which engage multidisciplinary researchers.[40,41] Identifying key points of  
17  
18 intervention and outcomes of importance to patients are essential to both the development of  
19  
20 well-designed pragmatic trials and the implementation of efficient, patient focused clinical  
21  
22 services.  
23  
24  
25  
26

27  
28  
29 There is increasing focus on ensuring that palliative care services are available to and  
30  
31 accessed by individuals with non-malignant diseases – with emphasis on need, not  
32  
33 diagnosis.[42] Idiopathic pulmonary fibrosis is, as previously discussed, an under-researched  
34  
35 disease. We anticipate that the results of this study will provide fundamental information  
36  
37 considering the experiences and needs of individuals and their carers, both quantitatively and  
38  
39 qualitatively, and will therefore be disseminated via relevant clinical and research journals  
40  
41 and international conferences, encompassing both palliative care and respiratory specialities.  
42  
43  
44 The Chief Investigator and three of the Co-Investigators are Consultant Clinicians in  
45  
46 palliative medicine and respiratory specialities, which will enable the planning and provision  
47  
48 of appropriate palliative care services for both individuals with IPF and their carers, across  
49  
50 the illness trajectory. Furthermore, the lay representative involved with the project will be  
51  
52 supported to disseminate the results to relevant patient groups.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 This paper has explored the incidence and symptoms of idiopathic pulmonary fibrosis, with  
4 discussion of the limited previous research undertaken in this area in terms of quality of life  
5 or experience of the disease. A paucity of research considering the experience and needs of  
6 carers was also identified. This protocol has presented a planned multicentre mixed-methods  
7 study in both England and Wales with people at different stages of IPF and their carers,  
8 utilising validated questionnaires and in-depth interviews. The results of the study may help  
9 healthcare professionals to plan and implement appropriate palliative care services for people  
10 with IPF, and appropriate support for their carers.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

### 23 **Acknowledgment:**

24 We wish to acknowledge the clinical teams who granted access and will support recruitment.  
25  
26  
27  
28  
29

### 30 **Competing interests:**

31 None  
32  
33  
34  
35

### 36 **Authors' contributions:**

37 AB is the Chief Investigator, designed the study and reviewed the manuscript. CS contributed  
38 to the protocol, reviewed the manuscript and will collect and analyse data. JB prepared the  
39 manuscript. KH, BHG and RH are site Principal Investigators. GG designed the study. AN  
40 designed the study and reviewed the manuscript.  
41  
42  
43  
44  
45  
46  
47  
48  
49

### 50 **Funding:**

51 This study was funded by [a project grant from Marie Curie Cancer Care \(reference](#)  
52 [C18659/A12565](#)  
53  
54  
55  
56  
57  
58  
59  
60



## REFERENCES

1. Raghu G, Weycker D, Edelsberg J, Williamson B, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2006;**174**(7):810 - 16
2. Swigris J, Stewart A, Gould M, Wilson S. Patients' perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives. *Health Qual Life Outcomes* 2005;**3**:61 - 69
3. Selman M, King T, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. *Ann Intern Med* 2001;**134**(2):136 - 51
4. Gribbin J, Hubbard R, Le Jeune I, Smith C, West J, Tata L. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. *Thorax* 2006;**61**(11):980 - 85
5. Navaratnam V, Fleming K, West J, et al. The rising incidence of idiopathic pulmonary fibrosis in the UK. *Thorax* 2011;**66**(6):462 - 67
6. Raghu G, Collard H, Egan J, et al., on behalf of the ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. *Am J Respir Crit Care Med* 2011;**183**(6):788 - 824
7. Lee J, McLaughlin S, Collard H. Comprehensive care of the patient with idiopathic pulmonary fibrosis. *Curr Opin Pulm Med* 2011;**17**(5):348 - 54
8. National Institute for Health and Care Excellence. Idiopathic pulmonary fibrosis: diagnosis and management of suspected idiopathic pulmonary fibrosis. <http://www.nice.org.uk/nicemedia/live/14183/64124/64124.pdf>, 2013.
9. World Health Organisation. WHO Definition of Palliative Care. <http://www.who.int/cancer/palliative/definition/en/>, 2012.

- 1  
2  
3 10. World Health Organisation. WHOQOL Measuring Quality of Life.  
4  
5 [http://www.who.int/mental\\_health/media/68.pdf](http://www.who.int/mental_health/media/68.pdf), 1997.  
6
- 7 11. Swigris J, Kuschner W, Jacobs S, Wilson S, Gould M. Health-related quality of life in  
8  
9 patients with idiopathic pulmonary fibrosis: a systematic review. *Thorax* 2005;**60**:558  
10  
11 - 94  
12
- 13 12. Krishnan V, McCormack M, Mathai S, et al. Sleep quality and health-related quality of  
14  
15 life in idiopathic pulmonary disease. *Chest* 2008;**134**(4):693 - 98  
16  
17
- 18 13. Tamioka H, Imanaka K, Hashimoto K, Iwasaki H. Health-related quality of life in  
19  
20 patients with idiopathic pulmonary fibrosis - cross-sectional and longitudinal study.  
21  
22 *Intern Med* 2007;**46**(18):1533 - 42  
23
- 24 14. Scheonheit G, Becattelli I, Cohen A. Living with idiopathic pulmonary fibrosis: an in-  
25  
26 depth qualitative survey of European patients. *Chron Respir Dis* 2011;**8**(4):225 - 31  
27  
28
- 29 15. Bajwah S, Koffman J, Higginson I, et al. 'I wish I knew more...' the end-of-life planning  
30  
31 and information needs for end-stage fibrotic interstitial lung disease: views of  
32  
33 patients, carers and health professionals. *BMJ Support Palliat Care* 2013;**3**:84 - 90  
34  
35
- 36 16. Patton M. *Qualitative Research and Evaluation Methods (3rd edn)*. London: Sage, 2002.  
37
- 38 17. Smith J, Flowers P, Larkin M. *Interpretative Phenomenological Analysis: Theory,*  
39  
40 *Method and Research*. Los Angeles: Sage, 2009: 1 - 232.  
41
- 42 18. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group.  
43  
44 *Annals of Medicine* 2001;**33**(5):337 - 43  
45  
46
- 47 19. Swigris J, Wilson S, Green K, Sprunger D, Brown K, Wamboldt F. Development of the  
48  
49 ATAQ-IPF: a tool to assess quality of life in IPF. *Health Qual Life Outcomes*  
50  
51 2010;**8**:77 - 85  
52
- 53 20. Bjelland I, Dahl A, Haug T, Neckelmann D. The validity of the Hospital Anxiety and  
54  
55 Depression Scale: An updated literature review. *J Psychosom Res* 2002;**52**(2):69 - 77  
56  
57

- 1  
2  
3 21. Dorman S, Byrne A, Edwards A. Which measurement scales should we use to measure  
4  
5 breathlessness in palliative care? A systematic review. *Palliat Med* 2007;**21**(3):177-91  
6  
7  
8 22. Birring S, Prudon B, Carr A, Singh S, Morgan M, Pavord I. Development of a symptom  
9  
10 specific health status measure for patients with chronic cough: Leicester Cough  
11  
12 Questionnaire (LCQ). *Thorax* 2003;**58**(4):339 - 43  
13  
14 23. Jones R, Hilldrup S, Hope-Gill B, Eccles R, Harrison N. Mechanical induction of cough  
15  
16 in Idiopathic Pulmonary Fibrosis. *Cough* 2011;**7**:2 - 12  
17  
18 24. Seamark D, Blake S, Seamark C, Halpin D. Living with severe chronic obstructive  
19  
20 pulmonary disease (COPD): perceptions of patients and their carers: An interpretative  
21  
22 phenomenological analysis. *Palliat Med* 2004;**18**(7):619 - 25  
23  
24  
25 25. Taubert M, Noble S, Nelson A. What challenges good palliative care provision out-of-  
26  
27 hours? A qualitative interview study of out-of-hours general practitioners. *Palliat*  
28  
29 *Med* 2011;**1**:13 - 18  
30  
31  
32 26. Orrevall Y, Tishelman C, Permert J. Home parenteral nutrition: A qualitative interview  
33  
34 study of the experiences of advanced cancer patients and their families. *Clin Nutr*  
35  
36 2005;**24**(6):961 - 70  
37  
38  
39 27. White Y, Grenyer B. The biopsychosocial impact of end-stage renal disease: the  
40  
41 experience of dialysis patients and their partners. *J Adv Nurs* 1999;**30**(6):1312 - 29  
42  
43 28. Cavers D, Hacking B, Erridge S, Morris P, Kendall M, Murray S. Adjustment and support  
44  
45 needs of glioma patients and their relatives: serial interviews. *Psychooncology*  
46  
47 2012;**DOI 10.1002/pon.3136**.  
48  
49 29. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research  
50  
51 (COREQ): a 32-item checklist for interviews and focus groups. *Int J Qual Health Care*  
52  
53 2007;**19**(6):349 - 57  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 30. Department of Health. Research Governance Framework for Health and Social Care (2nd  
4 edn.).  
5  
6  
7 [http://www.dh.gov.uk/prod\\_consum\\_dh/groups/dh\\_digitalassets/@dh/@en/document](http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4122427.pdf)  
8  
9 [s/digitalasset/dh\\_4122427.pdf](http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4122427.pdf) 2005.  
10  
11  
12 31. Welsh Assembly Government. Research Governance Framework for Health and Social  
13 Care in Wales (2nd ed.).  
14  
15  
16 [http://cymru.gov.uk/topics/health/research/word/publications/researchgovernance/?lan](http://cymru.gov.uk/topics/health/research/word/publications/researchgovernance/?lang=en)  
17 [g=en](http://cymru.gov.uk/topics/health/research/word/publications/researchgovernance/?lang=en)] 2009.  
18  
19  
20  
21 32. National Patient Safety Agency. Information Sheets and Consent Forms: Guidance for  
22 Researchers and Reviewers.  
23  
24 [www.nres.nhs.uk/EasySiteWeb/GatewayLink.aspx?allId=338](http://www.nres.nhs.uk/EasySiteWeb/GatewayLink.aspx?allId=338), 2011.  
25  
26  
27 33. United Kingdom. Mental Capacity Act 2005.  
28  
29 [http://www.opsi.gov.uk/acts/acts2005/ukpga\\_20050009\\_en\\_1](http://www.opsi.gov.uk/acts/acts2005/ukpga_20050009_en_1) 2005.  
30  
31  
32 34. United Kingdom. Data Protection Act 1998.  
33  
34 [http://www.opsi.gov.uk/acts/acts1998/ukpga\\_19980029\\_en\\_1](http://www.opsi.gov.uk/acts/acts1998/ukpga_19980029_en_1) 1998.  
35  
36  
37 35. Tischler V, D'Silva K, Cheetham A, Goring M, Calton T. Involving patients in research:  
38 the challenge of patient-centredness. *Int J Soc Psychiatry* 2010;**56**(6):623 - 33  
39  
40  
41 36. Moore B, Porteous C, Simon N. Pathways for Involving People in Social Care and Health  
42 Research in Wales: A Signposting Document. <http://www.involvingpeople.org.uk/>,  
43  
44 2007.  
45  
46  
47 37. Vale C, Fitzgibbon J, Hanley B, et al. Public involvement in clinical trials: Supplement to  
48 the briefing notes for researchers. [http://www.invo.org.uk/wp-](http://www.invo.org.uk/wp-content/uploads/2012/04/INVOLVEpublicinvolvementinclinicaltrialsBriefingnotes2012.pdf)  
49 [content/uploads/2012/04/INVOLVEpublicinvolvementinclinicaltrialsBriefingnotes20](http://www.invo.org.uk/wp-content/uploads/2012/04/INVOLVEpublicinvolvementinclinicaltrialsBriefingnotes2012.pdf)  
50 [12.pdf](http://www.invo.org.uk/wp-content/uploads/2012/04/INVOLVEpublicinvolvementinclinicaltrialsBriefingnotes2012.pdf), 2012.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 38. Greene J, Caracelli V, Graham W. Toward a conceptual framework for mixed-method  
4  
5 evaluation designs. *Education Evaluation and Policy Analysis* 1989;**11**(3):255 - 74  
6  
7  
8 39. Yardley L. Dilemmas in qualitative health research. *Psychology and Health*  
9  
10 2000;**15**(2):215 - 28  
11  
12 40. Byrne A, Hood K, Griffiths G, Maughan T. Design and conduct of research and clinical  
13  
14 trials. In: Walsh D, Caraceni A, Fainsinger R, et al., eds. *Palliative Medicine*.  
15  
16 Philadelphia: Saunders Elsevier, 2009.  
17  
18 41. Kaasa S, Hjermstad M, Loge J. Methodological and structural challenges in palliative  
19  
20 care research: how have we fared in the last decades? *Palliat Med* 2006;**20**(8):727 - 34  
21  
22  
23 42. Fallon M, Foley P. Rising to the challenge of palliative care for non-malignant disease.  
24  
25 *Palliat Med* 2012;**26**(2):99 - 100  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60